<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="data-paper"><?DTDIdentifier.IdentifierValue -//NPG//DTD XML Article//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName NPG_XML_Article.dtd?><?SourceDTD.Version 2.7.10?><?ConverterInfo.XSLTName nature2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Sci Data</journal-id><journal-id journal-id-type="iso-abbrev">Sci Data</journal-id><journal-title-group><journal-title>Scientific Data</journal-title></journal-title-group><issn pub-type="epub">2052-4463</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5058336</article-id><article-id pub-id-type="pii">sdata201689</article-id><article-id pub-id-type="doi">10.1038/sdata.2016.89</article-id><article-categories><subj-group subj-group-type="heading"><subject>Data Descriptor</subject></subj-group></article-categories><title-group><article-title>Human whole genome genotype and transcriptome data for Alzheimer&#x02019;s and other neurodegenerative diseases</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Allen</surname><given-names>Mariet</given-names></name><xref ref-type="aff" rid="a1">1</xref><xref ref-type="author-notes" rid="n1">*</xref></contrib><contrib contrib-type="author"><name><surname>Carrasquillo</surname><given-names>Minerva M.</given-names></name><xref ref-type="aff" rid="a1">1</xref><xref ref-type="author-notes" rid="n1">*</xref></contrib><contrib contrib-type="author"><name><surname>Funk</surname><given-names>Cory</given-names></name><xref ref-type="aff" rid="a2">2</xref></contrib><contrib contrib-type="author"><name><surname>Heavner</surname><given-names>Benjamin D.</given-names></name><xref ref-type="aff" rid="a2">2</xref></contrib><contrib contrib-type="author"><name><surname>Zou</surname><given-names>Fanggeng</given-names></name><xref ref-type="aff" rid="a1">1</xref></contrib><contrib contrib-type="author"><name><surname>Younkin</surname><given-names>Curtis S.</given-names></name><xref ref-type="aff" rid="a3">3</xref></contrib><contrib contrib-type="author"><name><surname>Burgess</surname><given-names>Jeremy D.</given-names></name><xref ref-type="aff" rid="a1">1</xref></contrib><contrib contrib-type="author"><name><surname>Chai</surname><given-names>High-Seng</given-names></name><xref ref-type="aff" rid="a4">4</xref></contrib><contrib contrib-type="author"><name><surname>Crook</surname><given-names>Julia</given-names></name><xref ref-type="aff" rid="a2">2</xref></contrib><contrib contrib-type="author"><name><surname>Eddy</surname><given-names>James A.</given-names></name><xref ref-type="aff" rid="a2">2</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Hongdong</given-names></name><xref ref-type="aff" rid="a2">2</xref></contrib><contrib contrib-type="author"><name><surname>Logsdon</surname><given-names>Ben</given-names></name><xref ref-type="aff" rid="a5">5</xref><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-0572-2569</contrib-id></contrib><contrib contrib-type="author"><name><surname>Peters</surname><given-names>Mette A.</given-names></name><xref ref-type="aff" rid="a5">5</xref></contrib><contrib contrib-type="author"><name><surname>Dang</surname><given-names>Kristen K.</given-names></name><xref ref-type="aff" rid="a5">5</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Xue</given-names></name><xref ref-type="aff" rid="a3">3</xref></contrib><contrib contrib-type="author"><name><surname>Serie</surname><given-names>Daniel</given-names></name><xref ref-type="aff" rid="a3">3</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Chen</given-names></name><xref ref-type="aff" rid="a4">4</xref><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-2638-3081</contrib-id></contrib><contrib contrib-type="author"><name><surname>Nguyen</surname><given-names>Thuy</given-names></name><xref ref-type="aff" rid="a1">1</xref></contrib><contrib contrib-type="author"><name><surname>Lincoln</surname><given-names>Sarah</given-names></name><xref ref-type="aff" rid="a1">1</xref></contrib><contrib contrib-type="author"><name><surname>Malphrus</surname><given-names>Kimberly</given-names></name><xref ref-type="aff" rid="a1">1</xref></contrib><contrib contrib-type="author"><name><surname>Bisceglio</surname><given-names>Gina</given-names></name><xref ref-type="aff" rid="a1">1</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Ma</given-names></name><xref ref-type="aff" rid="a1">1</xref></contrib><contrib contrib-type="author"><name><surname>Golde</surname><given-names>Todd E.</given-names></name><xref ref-type="aff" rid="a6">6</xref></contrib><contrib contrib-type="author"><name><surname>Mangravite</surname><given-names>Lara M.</given-names></name><xref ref-type="aff" rid="a5">5</xref><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-7841-3612</contrib-id></contrib><contrib contrib-type="author"><name><surname>Asmann</surname><given-names>Yan</given-names></name><xref ref-type="aff" rid="a2">2</xref></contrib><contrib contrib-type="author"><name><surname>Price</surname><given-names>Nathan D.</given-names></name><xref ref-type="aff" rid="a2">2</xref></contrib><contrib contrib-type="author"><name><surname>Petersen</surname><given-names>Ronald C.</given-names></name><xref ref-type="aff" rid="a7">7</xref></contrib><contrib contrib-type="author"><name><surname>Graff-Radford</surname><given-names>Neill R.</given-names></name><xref ref-type="aff" rid="a8">8</xref></contrib><contrib contrib-type="author"><name><surname>Dickson</surname><given-names>Dennis W.</given-names></name><xref ref-type="aff" rid="a1">1</xref></contrib><contrib contrib-type="author"><name><surname>Younkin</surname><given-names>Steven G.</given-names></name><xref ref-type="aff" rid="a1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ertekin-Taner</surname><given-names>Nil&#x000fc;fer</given-names></name><xref ref-type="corresp" rid="c1">a</xref><xref ref-type="aff" rid="a1">1</xref><xref ref-type="aff" rid="a8">8</xref></contrib><aff id="a1"><label>1</label><institution>Mayo Clinic, Department of Neuroscience</institution>, 4500 San Pablo Road, Jacksonville, Florida 32224, <country>USA</country></aff><aff id="a2"><label>2</label><institution>Institute for Systems Biology</institution>, 401 Terry Ave N., Seattle, Washington 98109, <country>USA</country></aff><aff id="a3"><label>3</label><institution>Mayo Clinic, Department of Health Sciences Research</institution>, 4500 San Pablo Road, Jacksonville, Florida 32224, <country>USA</country></aff><aff id="a4"><label>4</label><institution>Mayo Clinic, Department of Health Sciences Research</institution>, 200 First Street, Rochester, Minnesota 55905, <country>USA</country></aff><aff id="a5"><label>5</label><institution>Sage Bionetworks</institution>, 1100 Fairview Ave. N., Seattle, Washington 98109, USA</aff><aff id="a6"><label>6</label><institution>University of Florida, Center for Translational Research in Neurodegenerative Diseases</institution>, 1275 Center Dr, Gainesville, Florida 32611, <country>USA</country></aff><aff id="a7"><label>7</label><institution>Mayo Clinic, Department of Neurology</institution>, 200 First Street, Rochester, Minnesota 55905, <country>USA</country></aff><aff id="a8"><label>8</label><institution>Mayo Clinic, Department of Neurology</institution>, 4500 San Pablo Road, Jacksonville, Florida 32224, <country>USA</country></aff></contrib-group><author-notes><corresp id="c1"><label>a</label>
N.E.-T. (email: <email>taner.nilufer@mayo.edu</email>).</corresp><fn id="n1"><label>*</label><p>These authors contributed equally to this work</p></fn><fn id="con"><label/><p>M.A. helped with draft of the manuscript, analyzed data, contributed to the Mayo eGWAS and oversaw the Mayo Pilot RNAseq and Mayo RNAseq studies; M.M.C. helped with draft of manuscript, analyzed data, co-led the Mayo LOAD GWAS, and oversaw the Mayo Pilot RNAseq and Mayo RNAseq studies; C.F. analyzed data for Mayo Pilot RNAseq and Mayo RNAseq; B.D.H. analyzed data for Mayo Pilot RNAseq and Mayo RNAseq; F.Z. analyzed data and oversaw the Mayo eGWAS; C.S.Y. analyzed and databased data for all studies; J.D.B. analyzed data for Mayo eGWAS, Mayo Pilot RNAseq and Mayo RNAseq; H.-S.C. analyzed data for Mayo eGWAS; J.C. provided statistical support; J.A.E. analyzed data for Mayo Pilot RNAseq and Mayo RNAseq; H.L. analyzed data for Mayo Pilot RNAseq and Mayo RNAseq; B.L. architected the data repository, deposited these data into the public portal and manage data dissemination; M.A.P. architected the data repository, deposited these data into the public portal and manage data dissemination; K.K.D architected the data repository, deposited these data into the public portal and manage data dissemination; X.W. analyzed data for Mayo Pilot RNAseq and Mayo RNAseq; D.S. analyzed data for Mayo eGWAS, Mayo Pilot RNAseq and Mayo RNAseq; C.W. analyzed data for Mayo eGWAS; T.N. generated data; S.L. generated data; K.M. generated data; G.B. generated data; M.L. generated data; T.E.G. provided comments for the manuscript; L.M.M. architected the data repository, deposited these data into the public portal and manage data dissemination; Y.A. analyzed data for Mayo Pilot RNAseq and Mayo RNAseq; N.P. oversaw bioinformatics analysis of Mayo Pilot RNAseq and Mayo RNAseq; R.C.P. provided patient material and data; N.R.G.-R. provided patient material and data; D.W.D. provided patient material and data; S.G.Y. analyzed data, designed and led the Mayo GWAS, wrote the manuscript; N.E.-T. analyzed data, designed and led the Mayo eGWAS, Mayo Pilot RNAseq and Mayo RNAseq studies and wrote the manuscript.</p></fn></author-notes><pub-date pub-type="epub"><day>11</day><month>10</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>3</volume><elocation-id>160089</elocation-id><history><date date-type="received"><day>08</day><month>04</month><year>2016</year></date><date date-type="accepted"><day>31</day><month>08</month><year>2016</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2016, The Author(s)</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>The Author(s)</copyright-holder><license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><!--author-paid--><license-p>This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article&#x02019;s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link> Metadata associated with this Data Descriptor is available at <ext-link ext-link-type="uri" xlink:href="http://www.nature.com/sdata/">http://www.nature.com/sdata/</ext-link> and is released under the CC0 waiver to maximize reuse.
</license-p></license></permissions><related-article xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" related-article-type="data-paper-referrer" id="d33e19" xlink:href="10.1038/ng.305"/><related-article xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" related-article-type="data-paper-referrer" id="d33e154" xlink:href="10.1371/journal.pgen.1002707"/><related-article xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" related-article-type="data-paper-referrer" id="d33e411" xlink:href="10.1007/s00401-016-1576-7"/><abstract><p>Previous genome-wide association studies (GWAS), conducted by our group and others, have identified loci that harbor risk variants for neurodegenerative diseases, including Alzheimer's disease (AD). Human disease variants are enriched for polymorphisms that affect gene expression, including some that are known to associate with expression changes in the brain. Postulating that many variants confer risk to neurodegenerative disease via transcriptional regulatory mechanisms, we have analyzed gene expression levels in the brain tissue of subjects with AD and related diseases. Herein, we describe our collective datasets comprised of GWAS data from 2,099 subjects; microarray gene expression data from 773 brain samples, 186 of which also have RNAseq; and an independent cohort of 556 brain samples with RNAseq. We expect that these datasets, which are available to all qualified researchers, will enable investigators to explore and identify transcriptional mechanisms contributing to neurodegenerative diseases.</p></abstract><kwd-group kwd-group-type="npg.subject"><title>Subject terms</title><kwd>Neurodegeneration</kwd><kwd>Genetics of the nervous system</kwd><kwd>Genome-wide association studies</kwd><kwd>RNA sequencing</kwd></kwd-group></article-meta></front><body><sec disp-level="1"><title>Background &#x00026; Summary</title><p>In the past decade GWAS identified risk loci for human diseases, including AD<sup><xref ref-type="bibr" rid="b1">1&#x02013;7</xref></sup> and other neurodegenerative diseases<sup><xref ref-type="bibr" rid="b8">8</xref>,<xref ref-type="bibr" rid="b9">9</xref></sup>. Despite this progress, a comprehensive understanding of the molecular mechanisms underlying these complex conditions remains elusive. This is partly due to the inability of the disease GWAS approach to identify the actual disease gene and the functional disease risk variants. We<sup><xref ref-type="bibr" rid="b10">10</xref></sup> and others<sup><xref ref-type="bibr" rid="b11">11</xref>,<xref ref-type="bibr" rid="b12">12</xref></sup> utilized combined gene expression GWAS (eGWAS) and disease GWAS to identify loci which harbor regulatory variants that confer disease risk and to nominate the actual disease genes at these loci. The underlying premise of these studies is that genetic variants that modulate expression levels of genes, which encode critical members of disease molecular pathways, will also influence disease risk<sup><xref ref-type="bibr" rid="b13">13</xref></sup>. If this is correct, then there should be significant overlap between disease GWAS and eGWAS variants, especially if assessed in the disease-relevant tissue. Indeed, in an eGWAS of brain tissue from subjects with AD and non-AD, comprised largely of other neurodegenerative diagnoses, we identified significant enrichment for disease GWAS variants for AD and other diseases<sup><xref ref-type="bibr" rid="b10">10</xref></sup>. We<sup><xref ref-type="bibr" rid="b14">14&#x02013;18</xref></sup> and others<sup><xref ref-type="bibr" rid="b8">8</xref>,<xref ref-type="bibr" rid="b19">19&#x02013;22</xref></sup> determined that many of the risk variants for AD and other neurodegenerative diseases influence brain levels of genes that are nearby in the genome. These studies implicate the genes that are likely to be involved in disease pathways, nominate regulatory variants as the functional disease risk factors and provide testable hypotheses for their downstream effects.</p><p>Most large-scale gene expression studies in human brains published to date<sup><xref ref-type="bibr" rid="b10">10</xref>,<xref ref-type="bibr" rid="b19">19</xref>,<xref ref-type="bibr" rid="b20">20</xref>,<xref ref-type="bibr" rid="b23">23</xref></sup> utilize microarray-based gene or exon arrays. Despite the versatility, cost-effectiveness and large-scale utility, this approach has limitations, including restricted dynamic range, lack of probes for all known gene isoforms and confinement of assays to known transcripts. RNA sequencing (RNAseq) provides an attractive alternative that can surpass these limitations and provide much more in-depth information about the human transcriptome in a high-throughput manner<sup><xref ref-type="bibr" rid="b24">24</xref></sup>. To expand our prior work on the human transcriptome based on microarray approaches and to evaluate gene/exon/isoform levels in a comparative fashion between AD and other neurodegenerative diseases, we have generated RNAseq data on brain samples from both a subset of the subjects that underwent microarray transcriptome studies<sup><xref ref-type="bibr" rid="b18">18</xref></sup> and also an independent cohort. These datasets will be of utility in performing expression quantitative trait loci (eQTL), expression profiling and network analyses to facilitate interpretation of genetic associations and further understanding of disease-mediated changes in transcriptional regulation.</p><p>The present report is a description of the large-scale human genetic, and both microarray- and RNAseq-based transcriptome datasets we generated. The datasets described in this report have been made available to the research community through the Accelerating Medicines Partnership in Alzheimer&#x02019;s Disease (AMP-AD) Knowledge Portal (Data Citation 1). The portal is hosted in the Synapse software platform<sup><xref ref-type="bibr" rid="b25">25</xref></sup> from Sage Bionetworks as part of a series of datasets developed in support of the AMP-AD Target Identification and Preclinical Validation Project. The AMP-AD consortium includes six academic teams that will be generating genomic data from human brain or blood samples collected from more than 10 cohorts. Datasets are hosted in a common environment with standardized meta-data and annotations to facilitate cross-cohort query, access, and analysis. Each dataset provides a unique perspective on AD; therefore, datasets differ in types, generation protocols, and underlying patient characteristics. Together, this collection represents to date the most comprehensive collection of human genomic data in the field and, as such, it will be invaluable to a broad set of researchers.</p><p>The datasets described herein include the following: (1) late-onset AD GWAS<sup><xref ref-type="bibr" rid="b1">1</xref></sup> (Mayo LOAD GWAS) on 2,099 subjects (Data Citation 2); (2) Mayo eGWAS<sup><xref ref-type="bibr" rid="b10">10</xref></sup> on 773 samples from the cerebellum (CER) and temporal cortex (TCX) brain regions from a subset of Mayo LOAD GWAS participants (Data Citations 3,4); (3) Mayo Pilot RNAseq<sup><xref ref-type="bibr" rid="b18">18</xref></sup> generated on a subset of 186 TCX samples from the Mayo eGWAS (Data Citation 5); (4) Mayo RNAseq on an independent cohort of 556 TCX<sup><xref ref-type="bibr" rid="b26">26</xref></sup> (Data Citation 6) and CER (Data Citation 7) samples from subjects with AD, progressive supranuclear palsy (PSP), pathologic aging and elderly controls without neurodegenerative diseases. This report provides a comprehensive understanding of these cohorts, a detailed description of subjects, samples, data generation, and quality control (QC) as well as instructions to access these rich datasets by the scientific community.</p></sec><sec disp-level="1"><title>Methods</title><p>The repository of human whole genome genotype and transcriptome data described herein (<xref ref-type="table" rid="t1">Table 1</xref>,<xref ref-type="fig" rid="f1">Fig. 1</xref>) consist of the following resources some of which have previously been published: Previously published datasets include whole genome genotype data from the <bold>Mayo LOAD GWAS</bold><sup><xref ref-type="bibr" rid="b1">1</xref></sup> (Data Citation 2) and microarray-based whole transcriptome data from the <bold>Mayo eGWAS</bold><sup><xref ref-type="bibr" rid="b10">10</xref></sup> (Data Citations 3,4). Next-generation RNA-sequencing (<bold>RNAseq</bold>) data from a subset of the patients from the Mayo Clinic eGWAS, referred to as the &#x02018;<bold>Mayo Pilot RNAseq</bold>&#x02019; (Data Citation 5), was published in part<sup><xref ref-type="bibr" rid="b18">18</xref></sup>. A non-overlapping cohort with RNAseq-based transcriptome data named &#x02018;<bold>Mayo RNAseq</bold>&#x02019; (Data Citations 6,7) has also been published in part<sup><xref ref-type="bibr" rid="b26">26</xref></sup>. For a comprehensive description of the overall repository, the data from the published studies are also described herein, albeit in an abbreviated fashion. These four study cohorts will be referred to by their names as mentioned above, preceded by letters A-D (<xref ref-type="table" rid="t1">Table 1</xref>) henceforth.</p><sec disp-level="2"><title>Study Populations</title><p>All of this work was approved by the Mayo Clinic Institutional Review Board. All human subjects or their next of kin provided informed consent. The characteristics of the four study populations are as follows:</p><sec disp-level="3"><title>Mayo LOAD GWAS</title><p>The characteristics of the cohort for this study (Data Citation 2) were previously described in detail<sup><xref ref-type="bibr" rid="b1">1</xref></sup>. Briefly, this is a LOAD case versus control study composed in total of 2,099 subjects sourced from three different series, namely: Mayo Clinic Jacksonville, Mayo Clinic Rochester and Mayo Clinic Brain Bank series. These series are respectively termed as JS, RS and AUT in the GWAS publication<sup><xref ref-type="bibr" rid="b1">1</xref></sup> (<xref ref-type="table" rid="t1">Table 1</xref>). Subjects in the Mayo Clinic Jacksonville and Mayo Clinic Rochester series were diagnosed clinically. These series consisted of 353 LOAD cases versus 331 controls; and 245 LOAD cases versus 701 controls. The Mayo Clinic Brain Bank series is a post-mortem cohort that consists of 246 LOAD cases versus 223 controls. All subjects were North American Caucasians. All clinical LOAD subjects were diagnosed as probable or possible AD, according to NINCDS-ADRDA criteria<sup><xref ref-type="bibr" rid="b27">27</xref></sup>. All clinical controls had a clinical dementia rating score of 0. LOAD subjects in the Mayo Clinic Brain Bank series met neuropathologic criteria for definite AD and had a Braak score of &#x02265;4.0 (ref. <xref ref-type="bibr" rid="b28">28</xref>), while controls did not meet neuropathologic criteria for AD, and each had Braak score of &#x02264;2.5, which is an intermediary level of neurofibrillary tangle pathology between Braak score of 2 and 3; but most controls had neuropathologies unrelated to AD, including vascular dementia, frontotemporal dementia, dementia with Lewy bodies, multi-system atrophy, amyotrophic lateral sclerosis, and progressive supranuclear palsy. Ages, <italic>APOE &#x003b5;4</italic> genotype and sex distribution for the Mayo LOAD GWAS cohort are shown in <xref ref-type="table" rid="t2">Table 2</xref>. This study only included subjects with ages between 60 and 80 years, based on the assumption that much of the genetic risk for LOAD will be concentrated in this age group, especially given the age-dependent effects of the strongest AD risk variant apolipoprotein E &#x003b5;4 (<italic>APOE4</italic>)<sup><xref ref-type="bibr" rid="b28">28</xref></sup>. Age for the clinically diagnosed LOAD cases is defined as age at first diagnosis of AD, since age at onset is not always available. Age at entry into the study is used for the clinically diagnosed controls. Age at death is utilized for the cases and controls in the postmortem Mayo Clinic Brain Bank series, given that for this cohort, age at clinical diagnosis/ evaluation is not always available. Illumina Hap300 microarray genotypes from the subjects in these three case-control series were utilized to conduct a GWAS of LOAD risk<sup><xref ref-type="bibr" rid="b1">1</xref></sup>.</p></sec><sec disp-level="3"><title>Mayo eGWAS</title><p>This cohort was previously described in detail<sup><xref ref-type="bibr" rid="b10">10</xref></sup>. All subjects in the Mayo eGWAS (Data Citations 3,4) are a subset of the Mayo Clinic Brain Bank series from the Mayo LOAD GWAS (Data Citation 2) (<xref ref-type="fig" rid="f1">Fig. 1</xref>). The Mayo eGWAS is a whole transcriptome expression study in which brain samples from two different regions were analyzed, namely cerebellum (CER), which is relatively spared in AD, and temporal cortex (TCX), which is typically one of the first regions to be affected with AD neuropathology<sup><xref ref-type="bibr" rid="b29">29</xref></sup>. Transcriptome measurements were obtained from TCX of 202 AD subjects and from CER of 197 AD (<xref ref-type="table" rid="t1">Table 1</xref>). This study also included subjects without AD neuropathology, which are referred to as non-AD, given that many of these subjects had other neuropathologies. There were 197 non-AD subjects with TCX transcriptome measurements with the following neuropathologic diagnoses: progressive supranuclear palsy (PSP, <italic>n</italic>=107); Lewy body disease (LBD, <italic>n</italic>=25); corticobasal degeneration (CBD, <italic>n</italic>=22); frontotemporal lobar degeneration (FTLD, <italic>n</italic>=16); multiple system atrophy (MSA, <italic>n</italic>=11), vascular dementia (VaD, <italic>n</italic>=6); other (<italic>n</italic>=10). There were 177 non-AD subjects with CER transcriptome measurements that had the following neuropathologies: PSP (<italic>n</italic>=98); LBD (<italic>n</italic>=23); CBD (<italic>n</italic>=22); FTLD (<italic>n</italic>=15); MSA (<italic>n</italic>=7); VaD (<italic>n</italic>=4); other (<italic>n</italic>=8). Eighty-five percent of the subjects in the TCX cohort overlapped with those in the CER cohort. Demographics for the Mayo eGWAS subjects and samples, including RNA quality as assessed by RNA Integrity Numbers (RIN) are shown in <xref ref-type="table" rid="t2">Table 2</xref>.</p></sec><sec disp-level="3"><title>Mayo Pilot RNAseq</title><p>All subjects in the Mayo Pilot RNAseq study (Data Citation 5) are a subset of the Mayo eGWAS (Data Citations 3,4), and are therefore also participants of the Mayo Clinic Brain Bank series that was included in the Mayo LOAD GWAS (Data Citation 2) (<xref ref-type="fig" rid="f1">Fig. 1</xref>). The diagnostic categories in the Mayo Pilot RNAseq consist of 94 subjects with AD neuropathology and 92 PSP subjects, previously described<sup><xref ref-type="bibr" rid="b18">18</xref>,<xref ref-type="bibr" rid="b26">26</xref></sup>. PSP is a primary tauopathy characterized neuropathologically by neurofibrillary tangles (NFT) and tau-positive glial lesions<sup><xref ref-type="bibr" rid="b29">29</xref>,<xref ref-type="bibr" rid="b30">30</xref></sup>; and often presents clinically as a parkinsonian disorder. All PSP subjects were diagnosed neuropathologically by a single neuropathologist (DWD). For this study, only TCX samples were assessed (<xref ref-type="table" rid="t2">Table 2</xref>).</p></sec><sec disp-level="3"><title>Mayo RNAseq</title><p>The subjects from this cohort are non-overlapping with the cohorts described above. The Mayo RNAseq cohort was utilized to generate RNAseq-based whole transcriptome data from 278 TCX<sup><xref ref-type="bibr" rid="b26">26</xref></sup> (Data Citation 6) and 278 CER (Data Citation 7) samples. Two hundred thirty-eight subjects had both CER and TCX RNAseq and the rest had either CER or TCX RNAseq measurements based on tissue availability. CER samples were from the following diagnostic categories: 86 AD, 84 PSP, 28 pathologic aging and 80 controls without neurodegenerative diagnoses. TCX samples had the following diagnostic groups: 84 AD, 84 PSP, 30 pathologic aging and 80 controls. Control subjects each had Braak<sup><xref ref-type="bibr" rid="b28">28</xref></sup> NFT stage of 3.0 or less, CERAD<sup><xref ref-type="bibr" rid="b31">31</xref></sup> neuritic and cortical plaque densities of 0 (none) or 1 (sparse) and lacked any of the following pathologic diagnoses: AD, Parkinson&#x02019;s disease (PD), DLB, VaD, PSP, motor neuron disease (MND), CBD, Pick&#x02019;s disease (PiD), Huntington&#x02019;s disease (HD), FTLD, hippocampal sclerosis (HipScl) or dementia lacking distinctive histology (DLDH). Subjects with pathologic aging also lacked the above diagnoses and had Braak NFT stage of 3.0 or less, but had CERAD neuritic and cortical plaque densities of 2 or more. None of the pathologic aging subjects had a clinical diagnosis of dementia or mild cognitive impairment. Given the presence of amyloid plaques, but not tangles and the absence of dementia, pathologic aging is considered to be either a prodrome of AD or a condition, in which there is resistance to the development of NFT and/or dementia<sup><xref ref-type="bibr" rid="b32">32</xref></sup>.</p><p>Within the Mayo RNAseq cohort (Data Citations 6,7), all AD and PSP subjects were from the Mayo Clinic Brain Bank, and all pathologic aging subjects were obtained from the Banner Sun Health Institute. Thirty-four control CER and 31 control TCX samples were from the Mayo Clinic Brain Bank, and the remaining control tissue was from the Banner Sun Health Institute. All subjects were North American Caucasians. All but control subjects, had ages at death &#x02265;60, and a more relaxed lower age cutoff of &#x02265;50 was applied for normal controls to achieve sample sizes similar to that of AD and PSP subjects. No upper age limit was imposed on this cohort, however when subjects had ages at death of &#x02265;90, their ages were recorded as &#x02018;90_or_above&#x02019; and shown as &#x02018;90&#x02019; in <xref ref-type="table" rid="t2">Table 2</xref> to protect patient confidentiality.</p><p><xref ref-type="table" rid="t2">Table 2</xref> details the demographic characteristics of the Mayo RNAseq cohort (Data Citations 6,7). PSP subjects tended to be younger than the other diagnostic groups. As expected, there was a greater frequency of <italic>APOE4</italic> positive subjects in the AD group, followed by pathologic aging, then PSP and control subjects. AD and pathologic aging subjects had greater female sex frequency (57%), followed by controls (49%), then PSP subjects (39%). RIN for all samples were selected to be &#x02265;5.0. Pathologic aging and control samples had slightly lower RINs than AD and PSP samples, due to limitations in availability of samples in these former diagnostic categories.</p></sec></sec><sec disp-level="2"><title>Molecular Data</title><sec disp-level="3"><title>Sample collection and processing</title><p>For the Mayo LOAD GWAS (A) (Data Citation 2), DNA samples were collected and processed as previously described<sup><xref ref-type="bibr" rid="b1">1</xref></sup>. For the antemortem Mayo Clinic Jacksonville and Mayo Clinic Rochester series, whole blood samples were collected in 10&#x02009;ml EDTA tubes followed by DNA extraction using AutoGenFlex STAR instrument (AutoGen), whereas cerebellar tissue was used for DNA extraction from the postmortem Mayo Clinic Brain Bank series using the Wizard Genomic DNA purification kit (Promega). Given limited amounts of DNA from samples in the Mayo Clinic Rochester series and Mayo Clinic Brain Bank series, whole genome amplification (WGA) was applied using the Illustra GenomiPhi V2 DNA Amplification Kit (GE Healthcare Bio-Sciences), in four 5&#x02009;ml reactions that utilized 5&#x02013;15&#x02009;ng genomic DNA as a template. Subsequent to the pooling of these reaction products, WGA DNA was subjected to quality control (QC) using SNP genotyping as previously described.</p><p>RNA extraction methods for the Mayo eGWAS<sup><xref ref-type="bibr" rid="b10">10</xref></sup> (B) (Data Citations 3,4) and Mayo Pilot RNAseq<sup><xref ref-type="bibr" rid="b18">18</xref></sup> (C) (Data Citation 5) were previously described. Total RNA was extracted from frozen brain samples using the Ambion RNAqueous kit (Life Technologies, Grand Island, NY) according to the manufacturer&#x02019;s instructions. Brain samples for the Mayo RNAseq (D) (Data Citations 6,7) study underwent RNA extractions via the Trizol/chloroform/ethanol method, followed by DNase and Cleanup of RNA using Qiagen RNeasy Mini Kit and Qiagen RNase -Free DNase Set. The quantity and quality of all RNA samples were determined by the Agilent 2100 Bioanalyzer using the Agilent RNA 6000 Nano Chip (Agilent Technologies, Santa Clara, CA). Samples had to have an RNA Integrity Number (RIN) &#x02265;5.0 for inclusion in either study (<xref ref-type="table" rid="t2">Table 2</xref>).</p></sec><sec disp-level="3"><title>Data generation</title><p>The genotype data for the Mayo LOAD GWAS (A) (Data Citation 2) was generated using HumanHap300-Duo Genotyping BeadChips<sup><xref ref-type="bibr" rid="b1">1</xref></sup>, which were processed with an Illumina BeadLab station at the Mayo Clinic Genotyping Shared Resource (currently Mayo Clinic Medical Genome Facility=MGF, Rochester, Minnesota) according to the manufacturer&#x02019;s protocols. Two samples were genotyped per chip for 318,237 SNPs across the genome. Genotype calls were made using the auto-calling algorithm in Illumina&#x02019;s BeadStudio 2.0 software.</p><p>For the Mayo eGWAS study (B) (Data Citations 3,4), transcript levels were measured using the Whole Genome DASL assay (Illumina, San Diego, CA) as previously described<sup><xref ref-type="bibr" rid="b10">10</xref></sup>. Probe annotations were done based on NCBI RefSeq, Build 36.2. The RNA samples were randomized across the chips and plates using a stratified approach to ensure balance with respect to diagnosis, age, gender, RIN and <italic>APOE</italic> genotype. Raw probe mRNA expression data were exported from GenomeStudio software (Illumina Inc.) and preprocessed for background correction, variance stabilizing transformation, quantile normalization and probe filtering using the lumi package of BioConductor<sup><xref ref-type="bibr" rid="b33">33</xref></sup>.</p><p>Samples for both Mayo Pilot RNAseq (C) (Data Citation 5) and Mayo RNAseq (D) (Data Citations 6,7) studies were randomized prior to transfer to the Mayo Clinic MGF Gene Expression Core for library preparation and then the Sequencing Core for RNA sequencing. Mayo Pilot RNAseq (C) (Data Citation 5) AD and PSP samples were randomized across flowcells, taking into account age at death, sex and RIN. These samples underwent library preparation and sequencing at different times and therefore should be considered as separate datasets. Likewise, Mayo RNAseq (D) of TCX<sup><xref ref-type="bibr" rid="b26">26</xref></sup> and CER samples (Data Citations 6,7, respectively) underwent RNAseq at different times. These samples were randomized across flowcells, taking into account age at death, sex, RIN, Braak stage and diagnosis. The TruSeq RNA Sample Prep Kit (Illumina, San Diego, CA) was used for library preparation from all samples. The library concentration and size distribution was determined on an Agilent Bioanalyzer DNA 1000 chip. All samples were run in triplicates using barcoding (3 samples per flowcell lane). For Mayo Pilot RNAseq (C) (Data Citation 5) samples, 50 base-pair, paired-end sequencing was done, whereas Mayo RNAseq (D) (Data Citations 6,7) samples underwent 101&#x02009;bp, paired-end sequencing.</p></sec><sec disp-level="3"><title>Data Processing</title><p>Mayo LOAD GWAS (A) (Data Citation 2) genotypes from Illumina BeadStudio 2.0 software were utilized to generate lgen, map and fam files that were imported into PLINK<sup><xref ref-type="bibr" rid="b34">34</xref></sup> and converted to binary ped (.bed) and map (.bim) files, which are deposited together with PLINK format fam and covariate files (DOI and descriptions for each these files are provided in <xref ref-type="table" rid="t3">Table 3</xref> (available online only)).</p><p>The Mayo eGWAS WG-DASL microarray expression dataset from TCX and CER (B) includes covariates and probe expression levels (Data Citation 3), which are preprocessed as published<sup><xref ref-type="bibr" rid="b10">10</xref></sup> and described above. The Mayo eGWAS &#x02018;eSNP Results&#x02019; (Data Citation 4) are the eQTL results from the test of association between the Mayo LOAD GWAS (Data Citation 2) genotypes and the WG-DASL gene expression measures analyzed by multivariable linear regression using an additive model in PLINK<sup><xref ref-type="bibr" rid="b34">34</xref></sup>, as published previously<sup><xref ref-type="bibr" rid="b10">10</xref></sup> (DOI and descriptions for each these files are provided in <xref ref-type="table" rid="t3">Table 3</xref> (available online only)). These analysis used preprocessed probe transcript levels as traits, SNP minor allele dosage as the independent variable, and adjusted for the following covariates: <italic>APOE</italic> &#x003b5;4 dosage (0, 1, 2), age at death, sex, PCR plate, RIN and adjusted RIN squared (RIN-RINmean)<sup><xref ref-type="bibr" rid="b2">2</xref></sup>. Analyses were limited to SNP-probe pairs that were in-<italic>cis</italic>, defined as +/&#x02212;100&#x02009;kb of the targeted gene according to NCBI Build 36. The ADs and non&#x02013;ADs were analyzed both separately and jointly. The joint analyses included diagnosis as an additional covariate (AD=1, non&#x02013;AD=0). Results of analyses for both the genotyped SNPs as well as genotypes imputed to HapMap2 reference are provided. HapMap2 imputations were done as described<sup><xref ref-type="bibr" rid="b10">10</xref></sup>. The eGWAS results were previously made available through the NIAGADS repository (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.niagads.org/datasets/ng00025">https://www.niagads.org/datasets/ng00025</ext-link>).</p><p>The Mayo Pilot RNAseq<sup><xref ref-type="bibr" rid="b18">18</xref></sup> (Data Citation 5), Mayo RNAseq TCX<sup><xref ref-type="bibr" rid="b26">26</xref></sup> and CER data (Data Citations 6,7, respectively) were processed using the same analytic pipeline. Read alignments were done using the SNAPR software<sup><xref ref-type="bibr" rid="b35">35</xref></sup>, an RNA sequence aligner based on SNAP, using GRCh38 reference and Ensembl v77 gene models. Outputs include per-sample gene and transcript counts, which are merged into a single file per data type (gene or transcript) that contains data for all samples across all genes/transcripts (DOI and descriptions for each these files are provided in <xref ref-type="table" rid="t3">Table 3</xref> (available online only)). Alignment with SNAPR starts with the creation of hash indices built from both a reference genome GRCh38 and transcriptome GRCh38.77. SNAPR filters fastq reads by Phred score (&#x0003e;80% of the read must have a Phred score &#x0003e;= 20) and simultaneously aligns each read (or read pair) to both the genome and transcriptome. The best alignment is written to a sorted BAM file with read counts simultaneously tabulated and written for each sample. Read counts are given by gene ID and transcript ID (two separate files). We have previously tested the read counts generated by SNAPR to the read counts generated by HT-Seq and found them to be very comparable.</p><p>Post-processing was also performed using the same pipeline for these three RNAseq datasets as follows: The individual read count files produced by SNAPR are merged into a single file using two scripts: merge_count_files.R and a dataset-specific read-count merge script. These scripts generate the corresponding _counts.txt.gz files. The merged count files are normalized with the normalize_readcounts.R script, which uses the edgeR implementation of the trimmed mean of M-values (TMM) normalization method to calculate counts per million (CPM). These normalized counts are saved for both gene and transcript levels (DOI and descriptions for each these files are provided in <xref ref-type="table" rid="t3">Table 3</xref> (available online only)).</p></sec><sec disp-level="3"><title>Code Availability</title><p>The R script called merge_count_files.R<sup><xref ref-type="bibr" rid="b36">36</xref></sup> was used to merge the RNAseq read count files produced by SNAPR into a single file, and can be found at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://github.com/CoryFunk/AMP-AD-scripts/blob/master/combine_count_files.pl">https://github.com/CoryFunk/AMP-AD-scripts/blob/master/combine_count_files.pl</ext-link>. Also, the R script used to normalize the merged RNAseq read counts, called normalize_readcounts.R<sup><xref ref-type="bibr" rid="b36">36</xref></sup>, can be found at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://github.com/CoryFunk/AMP-AD-scripts/blob/master/tmm_normalization.R">https://github.com/CoryFunk/AMP-AD-scripts/blob/master/tmm_normalization.R</ext-link>.</p></sec></sec></sec><sec disp-level="1"><title>Data Records</title><p>Data available for studies A-D (, , , , , ; <xref ref-type="table" rid="t3">Table 3</xref> (available online only)) consists of a set of files that contain genomic, genetic or covariate data for a defined set of samples; analytic results are also provided when available. Data files can be found in the Sage Bionetworks AMP-AD Knowledge Portal (Data Citation 1) in study specific folders (and subfolders). Users can identify and search for data files and data descriptions using the unique Synapse ID and corresponding DOI provided in <xref ref-type="table" rid="t3">Table 3</xref> (available online only). Each sample within a study has a unique sample ID, this sample ID is consistent across all files within the study, and files in other studies where applicable. The relationship between studies and sample overlaps is illustrated in <xref ref-type="fig" rid="f1">Fig. 1</xref>. The samples in study C (Data Citation 5) are a subset of the samples in study B (Data Citation 3) which are likewise a subset of the samples in study A (Data Citation 2); the samples in study D (Data Citations 6,7) are independent of those in studies A-C. The Usage Notes section describes the data accession conditions, and the steps for requesting access.</p></sec><sec disp-level="1"><title>Technical Validation</title><sec disp-level="2"><title>Data QC</title><p>Mayo LOAD GWAS (A) (Data Citation 2) QC methods were previously published<sup><xref ref-type="bibr" rid="b1">1</xref></sup>. Briefly, using PLINK<sup><xref ref-type="bibr" rid="b34">34</xref></sup>, subjects with genotyping call rates of &#x0003c;90%, duplicate genotyping and/or sex-mismatches between recorded and deduced sex were eliminated from the dataset. All SNPs with genotyping call rates &#x0003c;90%, minor allele frequencies &#x0003c;0.01, and/or Hardy-Weinberg p values &#x0003c;0.001 were also eliminated. Prior to QC, 318,237 SNPs were genotyped in 2,465 subjects. The available data includes the 313,504 SNP genotypes from 2,099 subjects that passed these QC parameters.</p><p>The Mayo eGWAS<sup><xref ref-type="bibr" rid="b10">10</xref></sup> (B) (Data Citations 3,4) data was generated as follows: We annotated probes for presence of genetic variants by comparing their positions according to NCBI RefSeq, Build 36.3 to those of all variants within dbSNP131 and identified the list of probes that have &#x02265;1 variants within their sequence. We depict this information in the files for the Mayo eGWAS, &#x02018;eSNP Results&#x02019; (Data Citation 4) (<xref ref-type="table" rid="t3">Table 3</xref> (available online only)), by including &#x02018;SNP-In-Probe&#x02019; column, which has &#x02018;TRUE&#x02019; if the probe sequence harbors &#x02265;1 SNP, and &#x02018;FALSE&#x02019;, otherwise. We also calculated for each probe within each analytic group, percent detection rate above background. Probes that are detected in &#x0003e;12.5%, &#x0003e;25%, &#x0003e;50% and &#x0003e;75% of the subjects in each analytic group are annotated by four separate columns within the &#x02018;eSNP Results&#x02019; (Data Citation 4) from the eGWAS that included HapMap2 imputed genotypes, described below. The purpose of these annotation columns is to enable others the flexibility to impose cutoffs based on presence/absence of variants within probe sequence and/or probe detection rates while providing the full dataset for completeness. The Mayo eGWAS (Data Citation 3,Data Citation 4) also included replicate samples as described for QC and to estimate intraclass coefficients (ICC), which is the between-subject variance, as a percentage of the total variance in probe expression<sup><xref ref-type="bibr" rid="b10">10</xref></sup>. There were 4 AD and 4 non-AD temporal cortex samples that were measured in 5 replicates; and 10 AD and 5 non-AD cerebellar sample replicates across five plates. Universal human RNA (UHR) samples were also run on each PCR plate as part of QC. The expression phenotypes include results from only one of the replicate subjects selected randomly and exclude UHR results. It should be noted that 3 AD and 9 non-AD subjects for TCX, and 4 AD subjects for CER, do not have associated GWAS genotypes as they did not pass&#x02265;1 GWAS QC parameter described above.</p><p>For the Mayo Pilot RNAseq<sup><xref ref-type="bibr" rid="b18">18</xref></sup> (C) (Data Citation 5) data principal components analysis (PCA) identified 2 outliers in the AD and 4 in the PSP cohort. The covariates for these subjects were set to missing (=NA) in the respective covariate files (DOI and descriptions for these files are provide in <xref ref-type="table" rid="t3">Table 3</xref> (available online only)). Hence, although 96 AD and 96 PSP subjects underwent sequencing in the Mayo Pilot RNAseq study, 94 AD and 92 PSP subjects were retained for analyses. It should be noted that of these subjects, 1 AD and 7 PSP subjects lack GWAS data due to either having genotype counts &#x0003c;90% or failing sex checks. PCA identified no outliers in the Mayo RNAseq (D) of TCX<sup><xref ref-type="bibr" rid="b26">26</xref></sup> samples (Data Citation 6) but 2 such subjects in the CER analyses (Data Citation 7). The covariate data in the relevant CER files for these two subjects were set to missing. We likewise assessed the RNASeq data for sex discrepancies based on Y chromosome gene expression and documented sex and identified 2 subjects with mis-matched sex for both TCX and CER, plus a third subject in the CER cohort. These were also set to missing in the covariate files. At the time of this publication, the Mayo RNAseq subjects did not have GWAS genotypes deposited on Synapse.</p></sec></sec><sec disp-level="1"><title>Usage Notes</title><p>The data described herein is available for use by the research community and has been deposited in the AMP-AD Knowledge Portal (). <xref ref-type="table" rid="t3">Table 3</xref> (available online only) provides a detailed description of the files deposited for the four studies, their specific Synapse identifiers (IDs), DOIs, the types of files and definitions of the column headers. These files (, , , , , ), and their assigned DOIs will be maintained in perpetuity in the AMP-AD Knowledge Portal (). Access to all of these files is enabled through the Sage Bionetworks, Synapse repository; and a subset of the files for the Mayo LOAD GWAS () and the Mayo eGWAS (, ) are also available via NIAGADS (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.niagads.org">www.niagads.org</ext-link>).</p><p>The AMP-AD Knowledge Portal hosts data derived from multiple cohorts that were generated as part of or used in support of the AMP-AD Target Identification and Preclinical Validation project (). The portal uses the Synapse software platform<sup><xref ref-type="bibr" rid="b25">25</xref></sup> for backend support, providing users with both web-based and programmatic access to data files. All data files in the portal are annotated using a standard vocabulary to enable users to search for relevant content across the AMP-AD datasets using programmatic queries. Data is stored in a cloud based manner hosted by Amazon web services (AWS), which enables user to execute cloud-based compute. Detailed descriptions including data processing, QC metrics, and assay and cohort specific variables are provided for each file as applicable.</p><p>Access for the data described herein is controlled in a manner set forth by the institutional review board (IRB) at the Mayo Clinic. All data use terms include: (1) maintenance of data in a secure and confidential manner, (2) respect for the privacy of study participants, (3) citation of the data contributors in any publications resulting from data use, and (4) informing data contributors of resultant publications. Specific data use terms are provided for each dataset (, , , ) under the header &#x02018;Terms of use&#x02019;; users must register for a Synapse account and provide electronic agreement to these terms prior to accessing the study files. Access to the Mayo LOAD GWAS data (A) () requires a data use certificate (doi:10.7303/syn2954402.2). User approvals are managed by the Synapse Access and Compliance Team (ACT).</p><p>Data on the AMP-AD Knowledge Portal are annotated with a common dictionary of terms (doi:10.7303/syn5478487.2) to enable querying of the data using the Synapse analytical clients (R client: syn1834618, python client: syn1768504, command line client: syn2375225). Fields, their allowable values specific to the datasets described herein and the dictionary of annotations are shown in <xref ref-type="table" rid="t3">Table 3</xref> (available online only). These annotations can be used to identify files of interest within the available datasets and to filter on any of the fields using the allowable values from the dictionary (an example is shown here: doi:10.7303/syn5585666.1).</p></sec><sec disp-level="1"><title>Additional Information</title><p><bold>How to cite this article</bold>: Allen, M <italic>et al.</italic> Human whole genome genotype and transcriptome data for Alzheimer's and other neurodegenerative diseases. <italic>Sci. Data</italic> 3:160089 doi: 10.1038/sdata.2016.89 (2016).</p></sec><sec sec-type="supplementary-material" id="S1"><title>Supplementary Material</title><supplementary-material id="d33e612" content-type="local-data"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="sdata201689-isa1.zip"/></supplementary-material></sec></body><back><ref-list content-type="data-citations"><title>Data Citations</title><ref id="d1"><mixed-citation publication-type="data"><source>Synapse</source><year>2016</year><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://dx.doi.org/10.7303/syn2580853">http://dx.doi.org/10.7303/syn2580853</ext-link></mixed-citation></ref><ref id="d2"><mixed-citation publication-type="data"><source>Synapse</source><name><surname>Carrasquillo</surname><given-names>M. M.</given-names></name><year>2016</year><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://dx.doi.org/10.7303/syn2910256">http://dx.doi.org/10.7303/syn2910256</ext-link></mixed-citation></ref><ref id="d3"><mixed-citation publication-type="data"><source>Synapse</source><name><surname>Zou</surname><given-names>F.</given-names></name><year>2016</year><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://dx.doi.org/10.7303/syn3157225">http://dx.doi.org/10.7303/syn3157225</ext-link></mixed-citation></ref><ref id="d4"><mixed-citation publication-type="data"><source>Synapse</source><name><surname>Zou</surname><given-names>F.</given-names></name><year>2016</year><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://dx.doi.org/10.7303/syn3157249">http://dx.doi.org/10.7303/syn3157249</ext-link></mixed-citation></ref><ref id="d5"><mixed-citation publication-type="data"><source>Synapse</source><name><surname>Allen</surname><given-names>M.</given-names></name><year>2016</year><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://dx.doi.org/10.7303/syn3157268">http://dx.doi.org/10.7303/syn3157268</ext-link></mixed-citation></ref><ref id="d6"><mixed-citation publication-type="data"><source>Synapse</source><name><surname>Allen</surname><given-names>M.</given-names></name><year>2016</year><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://dx.doi.org/10.7303/syn3163039">http://dx.doi.org/10.7303/syn3163039</ext-link></mixed-citation></ref><ref id="d7"><mixed-citation publication-type="data"><source>Synapse</source><name><surname>Allen</surname><given-names>M.</given-names></name><year>2016</year><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://dx.doi.org/10.7303/syn5049298">http://dx.doi.org/10.7303/syn5049298</ext-link></mixed-citation></ref></ref-list><ack><p>We thank the patients and their families for the sample and tissue donations. Without their generosity, this research would not be possible. The Mayo Clinic Alzheimer's Disease Genetic Studies were led by Dr Nil&#x000fc;fer Ertekin-Taner and Dr Steven G. Younkin, Mayo Clinic, Jacksonville, FL using samples from the Mayo Clinic Study of Aging, the Mayo Clinic Alzheimer's Disease Research Center, and the Mayo Clinic Brain Bank. Data collection was supported through funding by NIA grants P50 AG016574, R01 AG032990, U01 AG046139, R01 AG018023, U01 AG006576, U01 AG006786, R01 AG025711, R01 AG017216, R01 AG003949, NINDS grant R01 NS080820, the GHR foundation, CurePSP Foundation, and support from Mayo Foundation. Samples collected through the Sun Health Research Institute Brain and Body Donation Program of Sun City, Arizona. The Brain and Body Donation Program is supported by the National Institute of Neurological Disorders and Stroke (U24 NS072026 National Brain and Tissue Resource for Parkinson&#x02019;s Disease and Related Disorders), the National Institute on Aging (P30 AG19610 Arizona Alzheimer&#x02019;s Disease Core Center), the Arizona Department of Health Services (contract 211002, Arizona Alzheimer&#x02019;s Research Center), the Arizona Biomedical Research Commission (contracts 4001, 0011, 05-901 and 1001 to the Arizona Parkinson's Disease Consortium) and the Michael J. Fox Foundation for Parkinson&#x02019;s Research. We thank Mrs. Kelly Viola for her assistance with revisions of this manuscript.</p></ack><ref-list><ref id="b1"><mixed-citation publication-type="journal"><name><surname>Carrasquillo</surname><given-names>M. M.</given-names></name>
<italic>et al.</italic>
<article-title>Genetic variation in PCDH11X is associated with susceptibility to late-onset Alzheimer's disease</article-title>. <source>Nat Genet</source>
<volume>41</volume>, <fpage>192</fpage>&#x02013;<lpage>198</lpage> (<year>2009</year>).<pub-id pub-id-type="pmid">19136949</pub-id></mixed-citation></ref><ref id="b2"><mixed-citation publication-type="journal"><name><surname>Harold</surname><given-names>D.</given-names></name>
<italic>et al.</italic>
<article-title>Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease</article-title>. <source>Nature genetics</source>
<volume>41</volume>, <fpage>1088</fpage>&#x02013;<lpage>1093</lpage> (<year>2009</year>).<pub-id pub-id-type="pmid">19734902</pub-id></mixed-citation></ref><ref id="b3"><mixed-citation publication-type="journal"><name><surname>Lambert</surname><given-names>J. C.</given-names></name>
<italic>et al.</italic>
<article-title>Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease</article-title>. <source>Nature genetics</source>
<volume>41</volume>, <fpage>1094</fpage>&#x02013;<lpage>1099</lpage> (<year>2009</year>).<pub-id pub-id-type="pmid">19734903</pub-id></mixed-citation></ref><ref id="b4"><mixed-citation publication-type="journal"><name><surname>Seshadri</surname><given-names>S.</given-names></name>
<italic>et al.</italic>
<article-title>Genome-wide analysis of genetic loci associated with Alzheimer disease</article-title>. <source>Jama</source>
<volume>303</volume>, <fpage>1832</fpage>&#x02013;<lpage>1840</lpage> (<year>2010</year>).<pub-id pub-id-type="pmid">20460622</pub-id></mixed-citation></ref><ref id="b5"><mixed-citation publication-type="journal"><name><surname>Naj</surname><given-names>A. C.</given-names></name>
<italic>et al.</italic>
<article-title>Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease</article-title>. <source>Nature genetics</source>
<volume>43</volume>, <fpage>436</fpage>&#x02013;<lpage>441</lpage> (<year>2011</year>).<pub-id pub-id-type="pmid">21460841</pub-id></mixed-citation></ref><ref id="b6"><mixed-citation publication-type="journal"><name><surname>Hollingworth</surname><given-names>P.</given-names></name>
<italic>et al.</italic>
<article-title>Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease</article-title>. <source>Nature genetics</source>
<volume>43</volume>, <fpage>429</fpage>&#x02013;<lpage>435</lpage> (<year>2011</year>).<pub-id pub-id-type="pmid">21460840</pub-id></mixed-citation></ref><ref id="b7"><mixed-citation publication-type="journal"><name><surname>Lambert</surname><given-names>J. C.</given-names></name>
<italic>et al.</italic>
<article-title>Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease</article-title>. <source>Nature genetics</source>
<volume>45</volume>, <fpage>1452</fpage>&#x02013;<lpage>1458</lpage> (<year>2013</year>).<pub-id pub-id-type="pmid">24162737</pub-id></mixed-citation></ref><ref id="b8"><mixed-citation publication-type="journal"><name><surname>Hoglinger</surname><given-names>G. U.</given-names></name>
<italic>et al.</italic>
<article-title>Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy</article-title>. <source>Nature genetics</source>
<volume>43</volume>, <fpage>699</fpage>&#x02013;<lpage>705</lpage> (<year>2011</year>).<pub-id pub-id-type="pmid">21685912</pub-id></mixed-citation></ref><ref id="b9"><mixed-citation publication-type="journal"><name><surname>Simon-Sanchez</surname><given-names>J.</given-names></name>
<italic>et al.</italic>
<article-title>Genome-wide association study reveals genetic risk underlying Parkinson's disease</article-title>. <source>Nature genetics</source>
<volume>41</volume>, <fpage>1308</fpage>&#x02013;<lpage>1312</lpage> (<year>2009</year>).<pub-id pub-id-type="pmid">19915575</pub-id></mixed-citation></ref><ref id="b10"><mixed-citation publication-type="journal"><name><surname>Zou</surname><given-names>F.</given-names></name>
<italic>et al.</italic>
<article-title>Brain expression genome-wide association study (eGWAS) identifies human disease-associated variants</article-title>. <source>PLoS Genet</source>
<volume>8</volume>, <fpage>e1002707</fpage> (<year>2012</year>).<pub-id pub-id-type="pmid">22685416</pub-id></mixed-citation></ref><ref id="b11"><mixed-citation publication-type="journal"><name><surname>Dixon</surname><given-names>A. L.</given-names></name>
<italic>et al.</italic>
<article-title>A genome-wide association study of global gene expression</article-title>. <source>Nature genetics</source>
<volume>39</volume>, <fpage>1202</fpage>&#x02013;<lpage>1207</lpage> (<year>2007</year>).<pub-id pub-id-type="pmid">17873877</pub-id></mixed-citation></ref><ref id="b12"><mixed-citation publication-type="journal"><name><surname>Emilsson</surname><given-names>V.</given-names></name>
<italic>et al.</italic>
<article-title>Genetics of gene expression and its effect on disease</article-title>. <source>Nature</source>
<volume>452</volume>, <fpage>423</fpage>&#x02013;<lpage>428</lpage> (<year>2008</year>).<pub-id pub-id-type="pmid">18344981</pub-id></mixed-citation></ref><ref id="b13"><mixed-citation publication-type="journal"><name><surname>Saykin</surname><given-names>A. J.</given-names></name>
<italic>et al.</italic>
<article-title>Genetic studies of quantitative MCI and AD phenotypes in ADNI: Progress, opportunities, and plans</article-title>. <source>Alzheimers Dement</source>
<volume>11</volume>, <fpage>792</fpage>&#x02013;<lpage>814</lpage> (<year>2015</year>).<pub-id pub-id-type="pmid">26194313</pub-id></mixed-citation></ref><ref id="b14"><mixed-citation publication-type="journal"><name><surname>Zou</surname><given-names>F.</given-names></name>
<italic>et al.</italic>
<article-title>Gene expression levels as endophenotypes in genome-wide association studies of Alzheimer disease</article-title>. <source>Neurology</source>
<volume>74</volume>, <fpage>480</fpage>&#x02013;<lpage>486</lpage> (<year>2010</year>).<pub-id pub-id-type="pmid">20142614</pub-id></mixed-citation></ref><ref id="b15"><mixed-citation publication-type="journal"><name><surname>Allen</surname><given-names>M.</given-names></name>
<italic>et al.</italic>
<article-title>Novel late-onset Alzheimer disease loci variants associate with brain gene expression</article-title>. <source>Neurology</source>
<volume>79</volume>, <fpage>221</fpage>&#x02013;<lpage>228</lpage> (<year>2012</year>).<pub-id pub-id-type="pmid">22722634</pub-id></mixed-citation></ref><ref id="b16"><mixed-citation publication-type="journal"><name><surname>Allen</surname><given-names>M.</given-names></name>
<italic>et al.</italic>
<article-title>Glutathione S-transferase omega genes in Alzheimer and Parkinson disease risk, age-at-diagnosis and brain gene expression: an association study with mechanistic implications</article-title>. <source>Mol Neurodegener</source>
<volume>7</volume>, <fpage>13</fpage> (<year>2012</year>).<pub-id pub-id-type="pmid">22494505</pub-id></mixed-citation></ref><ref id="b17"><mixed-citation publication-type="journal"><name><surname>Allen</surname><given-names>M.</given-names></name>
<italic>et al.</italic>
<article-title>Association of MAPT haplotypes with Alzheimer's disease risk and MAPT brain gene expression levels</article-title>. <source>Alzheimers Res Ther</source>
<volume>6</volume>, <fpage>39</fpage> (<year>2014</year>).<pub-id pub-id-type="pmid">25324900</pub-id></mixed-citation></ref><ref id="b18"><mixed-citation publication-type="journal"><name><surname>Allen</surname><given-names>M</given-names></name>
<italic>et al.</italic>
<article-title>Late-onset Alzheimer disease risk variants mark brain regulatory loci</article-title>. <source>Neurology: Genetics</source>
<volume>1</volume>, <fpage>e15</fpage> (<year>2015</year>).<pub-id pub-id-type="pmid">27066552</pub-id></mixed-citation></ref><ref id="b19"><mixed-citation publication-type="journal"><name><surname>Myers</surname><given-names>A. J.</given-names></name>
<italic>et al.</italic>
<article-title>A survey of genetic human cortical gene expression</article-title>. <source>Nature genetics</source>
<volume>39</volume>, <fpage>1494</fpage>&#x02013;<lpage>1499</lpage> (<year>2007</year>).<pub-id pub-id-type="pmid">17982457</pub-id></mixed-citation></ref><ref id="b20"><mixed-citation publication-type="journal"><name><surname>Webster</surname><given-names>J. A.</given-names></name>
<italic>et al.</italic>
<article-title>Genetic control of human brain transcript expression in Alzheimer disease</article-title>. <source>Am J Hum Genet</source>
<volume>84</volume>, <fpage>445</fpage>&#x02013;<lpage>458</lpage> (<year>2009</year>).<pub-id pub-id-type="pmid">19361613</pub-id></mixed-citation></ref><ref id="b21"><mixed-citation publication-type="journal"><name><surname>Chapuis</surname><given-names>J.</given-names></name>
<italic>et al.</italic>
<article-title>Increased expression of BIN1 mediates Alzheimer genetic risk by modulating tau pathology</article-title>. <source>Mol Psychiatry</source>
<volume>18</volume>, <fpage>1225</fpage>&#x02013;<lpage>1234</lpage> (<year>2013</year>).<pub-id pub-id-type="pmid">23399914</pub-id></mixed-citation></ref><ref id="b22"><mixed-citation publication-type="journal"><name><surname>Hazrati</surname><given-names>L. N.</given-names></name>
<italic>et al.</italic>
<article-title>Genetic association of CR1 with Alzheimer's disease: a tentative disease mechanism</article-title>. <source>Neurobiol Aging</source>
<volume>33</volume>, <fpage>2949 e5</fpage>&#x02013;<lpage>2949 e12</lpage> (<year>2012</year>).</mixed-citation></ref><ref id="b23"><mixed-citation publication-type="journal"><name><surname>Ramasamy</surname><given-names>A.</given-names></name>
<italic>et al.</italic>
<article-title>Genetic variability in the regulation of gene expression in ten regions of the human brain</article-title>. <source>Nat Neurosci</source>
<volume>17</volume>, <fpage>1418</fpage>&#x02013;<lpage>1428</lpage> (<year>2014</year>).<pub-id pub-id-type="pmid">25174004</pub-id></mixed-citation></ref><ref id="b24"><mixed-citation publication-type="journal"><name><surname>Montgomery</surname><given-names>S. B.</given-names></name>
<italic>et al.</italic>
<article-title>Transcriptome genetics using second generation sequencing in a Caucasian population</article-title>. <source>Nature</source>
<volume>464</volume>, <fpage>773</fpage>&#x02013;<lpage>777</lpage> (<year>2010</year>).<pub-id pub-id-type="pmid">20220756</pub-id></mixed-citation></ref><ref id="b25"><mixed-citation publication-type="journal"><name><surname>Derry</surname><given-names>J. M.</given-names></name>
<italic>et al.</italic>
<article-title>Developing predictive molecular maps of human disease through community-based modeling</article-title>. <source>Nature genetics</source>
<volume>44</volume>, <fpage>127</fpage>&#x02013;<lpage>130</lpage> (<year>2012</year>).<pub-id pub-id-type="pmid">22281773</pub-id></mixed-citation></ref><ref id="b26"><mixed-citation publication-type="journal"><name><surname>Allen</surname><given-names>M.</given-names></name>
<italic>et al.</italic>
<article-title>Gene expression, methylation and neuropathology correlations at progressive supranuclear palsy risk loci</article-title>. <source>Acta Neuropathol</source>
<volume>132</volume>, <fpage>197</fpage>&#x02013;<lpage>211</lpage> (<year>2016</year>).<pub-id pub-id-type="pmid">27115769</pub-id></mixed-citation></ref><ref id="b27"><mixed-citation publication-type="journal"><name><surname>McKhann</surname><given-names>G</given-names></name>
<italic>et al.</italic>
<article-title>Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease</article-title>. <source>Neurology</source>
<volume>34</volume>, <fpage>939</fpage>&#x02013;<lpage>944</lpage> (<year>1984</year>).<pub-id pub-id-type="pmid">6610841</pub-id></mixed-citation></ref><ref id="b28"><mixed-citation publication-type="journal"><name><surname>Farrer</surname><given-names>LA</given-names></name>
<italic>et al.</italic>
<article-title>Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium</article-title>. <source>Jama</source>
<volume>278</volume>, <fpage>1349</fpage>&#x02013;<lpage>1356</lpage> (<year>1997</year>).<pub-id pub-id-type="pmid">9343467</pub-id></mixed-citation></ref><ref id="b29"><mixed-citation publication-type="journal"><name><surname>Braak</surname><given-names>H.</given-names></name> &#x00026; <name><surname>Braak</surname><given-names>E.</given-names></name>
<article-title>Neuropathological stageing of Alzheimer-related changes</article-title>. <source>Acta Neuropathol (Berl)</source>
<volume>82</volume>, <fpage>239</fpage>&#x02013;<lpage>259</lpage> (<year>1991</year>).<pub-id pub-id-type="pmid">1759558</pub-id></mixed-citation></ref><ref id="b30"><mixed-citation publication-type="journal"><name><surname>Hauw</surname><given-names>J. J.</given-names></name>
<italic>et al.</italic>
<article-title>Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy)</article-title>. <source>Neurology</source>
<volume>44</volume>, <fpage>2015</fpage>&#x02013;<lpage>2019</lpage> (<year>1994</year>).<pub-id pub-id-type="pmid">7969952</pub-id></mixed-citation></ref><ref id="b31"><mixed-citation publication-type="journal"><name><surname>Mirra</surname><given-names>S. S.</given-names></name>
<italic>et al.</italic>
<article-title>Interlaboratory comparison of neuropathology assessments in Alzheimer's disease: a study of the Consortium to Establish a Registry for Alzheimer's Disease (CERAD)</article-title>. <source>J Neuropathol Exp Neurol</source>
<volume>53</volume>, <fpage>303</fpage>&#x02013;<lpage>315</lpage> (<year>1994</year>).<pub-id pub-id-type="pmid">8176413</pub-id></mixed-citation></ref><ref id="b32"><mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>J.</given-names></name>, <name><surname>Dickson</surname><given-names>D. W.</given-names></name>, <name><surname>Trojanowski</surname><given-names>J. Q.</given-names></name> &#x00026; <name><surname>Lee</surname><given-names>V. M.</given-names></name>
<article-title>The levels of soluble versus insoluble brain Abeta distinguish Alzheimer's disease from normal and pathologic aging</article-title>. <source>Exp Neurol</source>
<volume>158</volume>, <fpage>328</fpage>&#x02013;<lpage>337</lpage> (<year>1999</year>).<pub-id pub-id-type="pmid">10415140</pub-id></mixed-citation></ref><ref id="b33"><mixed-citation publication-type="journal"><name><surname>Du</surname><given-names>P.</given-names></name>, <name><surname>Kibbe</surname><given-names>W. A.</given-names></name> &#x00026; <name><surname>Lin</surname><given-names>S. M.</given-names></name>
<article-title>lumi: a pipeline for processing Illumina microarray</article-title>. <source>Bioinformatics</source>
<volume>24</volume>, <fpage>1547</fpage>&#x02013;<lpage>1548</lpage> (<year>2008</year>).<pub-id pub-id-type="pmid">18467348</pub-id></mixed-citation></ref><ref id="b34"><mixed-citation publication-type="journal"><name><surname>Purcell</surname><given-names>S.</given-names></name>
<italic>et al.</italic>
<article-title>PLINK: a tool set for whole-genome association and population-based linkage analyses</article-title>. <source>Am J Hum Genet</source>
<volume>81</volume>, <fpage>559</fpage>&#x02013;<lpage>575</lpage> (<year>2007</year>).<pub-id pub-id-type="pmid">17701901</pub-id></mixed-citation></ref><ref id="b35"><mixed-citation publication-type="journal"><name><surname>Magis</surname><given-names>A. T.</given-names></name>, <name><surname>Funk</surname><given-names>C. C.</given-names></name> &#x00026; <name><surname>Price</surname><given-names>N. D.</given-names></name>
<article-title>SNAPR: A Bioinformatics Pipeline for Efficient and Accurate RNA-Seq Alignment and Analysis</article-title>. <source>IEEE Life Sciences Letters</source>
<volume>1</volume>, <fpage>22</fpage>&#x02013;<lpage>25</lpage> (<year>2015</year>).</mixed-citation></ref><ref id="b36"><mixed-citation publication-type="journal"><name><surname>Funk</surname><given-names>C</given-names></name>. <article-title>AMP-AD-scripts: AMP-AD Fl-Mayo-ISB</article-title>. in <source>Zenodo</source>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dx.doi.org/10.5281/zenodo.56828">https://dx.doi.org/10.5281/zenodo.56828</ext-link> (<year>2016</year>).</mixed-citation></ref></ref-list><fn-group><fn fn-type="COI-statement"><p>Below are the disclosures for R.C.P.: Pfizer, Inc., and Janssen Alzheimer Immunotherapy: Chair, Data Monitoring Committee. Hoffman-La Roche, Inc.: Consultant. Merck, Inc.: Consultant. Genentech, Inc.: Consultant. Biogen, Inc.: Consultant. Eli Lilly &#x00026; Co.: Consultant. N.R.G.-R. has multicenter treatment study grants from Lilly and TauRx and consulted for Cytox. N.E.-T. has consulted for Cytox. The remaining authors declare no competing financial interests.</p></fn></fn-group></back><floats-group><fig id="f1"><label>Figure 1</label><caption><title>Overview of the relationship of the four genomic datasets herein described.</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="sdata201689-f1"/></fig><table-wrap position="float" id="t1"><label>Table 1</label><caption><title>Meta-data for each of the four studies.</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"><bold>Study Name</bold></th><th align="left" valign="top" charoff="50"><bold>Brief Description</bold></th><th align="left" valign="top" charoff="50"><bold>Study Cohort/Sample type</bold></th><th align="left" valign="top" charoff="50"><bold>N</bold></th><th align="left" valign="top" charoff="50"><bold>Cohort Characteristics</bold></th><th align="left" valign="top" charoff="50"><bold>Datatype</bold></th><th align="left" valign="top" charoff="50"><bold>Platform</bold></th><th align="left" valign="top" charoff="50"><bold>Reference</bold></th></tr></thead><tbody valign="top"><tr><td rowspan="3" align="left" valign="top" charoff="50">A. Mayo LOAD GWAS (Data Citation 2)</td><td rowspan="3" align="left" valign="top" charoff="50">LOAD Case control GWAS. Uses samples from 3 cohorts: Total 2,099 subjects (Post-QC). This data is used to identify loci associated with LOAD risk.</td><td align="left" valign="top" charoff="50">Mayo Clinic Jacksonville (JS)/Antemortem</td><td align="left" valign="top" charoff="50"><italic>N</italic>=353 cases, 331 controls</td><td align="left" valign="top" charoff="50">Clinical: AD Cases and Controls, collected at Mayo Clinic Jacksonville. Age at first diagnosis of AD or age at study entry: 60&#x02013;80.</td><td rowspan="3" align="left" valign="top" charoff="50">LOAD GWAS Genotypes, demographics</td><td rowspan="3" align="left" valign="top" charoff="50">Illumina Hap 300</td><td rowspan="3" align="left" valign="top" charoff="50">Carrasquillo <italic>et al.</italic><sup><xref ref-type="bibr" rid="b1">1</xref></sup>, Nature Genetics</td></tr><tr><td align="left" valign="top" charoff="50">Mayo Clinic Rochester (RS)/Antemortem</td><td align="left" valign="top" charoff="50"><italic>N</italic>=245 cases, 701 controls</td><td align="left" valign="top" charoff="50">Clinical: AD Cases and Controls, collected at Mayo Clinic Rochester. Age at first diagnosis of AD or age at study entry: 60&#x02013;80.</td></tr><tr><td align="left" valign="top" charoff="50">Mayo Clinic Brain Bank (AUT)/ Postmortem</td><td align="left" valign="top" charoff="50"><italic>N</italic>=246 cases, 223 controls</td><td align="left" valign="top" charoff="50">Post-mortem: AD Cases (Braak &#x02265;4.0) and Other Pathologies (Braak &#x02264;2.5). Age at death: 60&#x02013;80.</td></tr><tr><td rowspan="2" align="left" valign="top" charoff="50">B. Mayo eGWAS (Data Citations 3,4)</td><td rowspan="2" align="left" valign="top" charoff="50">WG-DASL gene expression measures for a subset of Mayo Brain Bank subjects that were included in the Mayo LOAD GWAS: RNA was isolated from two brain regions: TCX and CER. This data is utilized to identify loci associated with brain gene expression in subjects with AD, subjects with Other brain pathologies that do not meet criteria for AD (Non-AD), and the combined cohort.</td><td align="left" valign="top" charoff="50">Mayo Brain Bank/Temporal Cortex</td><td align="left" valign="top" charoff="50"><italic>N</italic>=202 AD, 197 Non-AD controls</td><td rowspan="2" align="left" valign="top" charoff="50">Post-mortem: AD Cases (Braak &#x02265;4.0) and Other Pathologies (Braak &#x02264;2.5). Age at death: 60&#x02013;80.</td><td rowspan="2" align="left" valign="top" charoff="50">Gene expression phenotypes, eGWAS results, covariates</td><td rowspan="2" align="left" valign="top" charoff="50">Illumina WG-DASL</td><td rowspan="2" align="left" valign="top" charoff="50">Zou <italic>et al.</italic><sup><xref ref-type="bibr" rid="b10">10</xref></sup>, PLoS Genetics</td></tr><tr><td align="left" valign="top" charoff="50">Mayo Brain Bank/Cerebellum</td><td align="left" valign="top" charoff="50"><italic>N</italic>=197 AD, 177 Non-AD controls</td></tr><tr><td align="left" valign="top" charoff="50">C. Mayo Pilot RNAseq (Data Citation 5)</td><td align="left" valign="top" charoff="50">RNAseq gene expression measures for a subset of Mayo Brain Bank subjects that were included in the Mayo LOAD GWAS: RNA was isolated from TCX. This data is utilized to identify loci associated with brain gene expression in subjects with AD and subjects with PSP.</td><td align="left" valign="top" charoff="50">Mayo Brain Bank/Temporal Cortex</td><td align="left" valign="top" charoff="50"><italic>N</italic>=94 AD, 92 PSP</td><td align="left" valign="top" charoff="50">Post-mortem: AD Cases (Braak &#x02265;4.0) and pathologic diagnosis of PSP (Braak&#x02264;2.5). Age at death: 60&#x02013;80.</td><td align="left" valign="top" charoff="50">Gene expression phenotypes, covariates</td><td align="left" valign="top" charoff="50">IlluminaHiSeq2000, 50 bp, paired end RNAseq</td><td align="left" valign="top" charoff="50">Allen <italic>et al.</italic><sup><xref ref-type="bibr" rid="b18">18</xref></sup>, Neurology:Genetics</td></tr><tr><td rowspan="2" align="left" valign="top" charoff="50">D. Mayo RNAseq (Data Citations 6,7)</td><td rowspan="2" align="left" valign="top" charoff="50">RNAseq gene expression measures for subjects from the Mayo Brain Bank non-overlapping with the Mayo LOAD GWAS, and also from Banner Sun Health Institute. RNA was isolated from two brain regions: TCX and CER. This data is utilized to compare brain gene expression between different pairwise diagnostic groups.</td><td align="left" valign="top" charoff="50">Mayo Brain Bank and Banner Sun Health/Temporal Cortex</td><td align="left" valign="top" charoff="50"><italic>N</italic>=84 AD, 84 PSP, 30 pathologic aging, 80 controls</td><td rowspan="2" align="left" valign="top" charoff="50">Post-mortem: AD Cases (Braak &#x02265;4.0), pathologic diagnoses of PSP (Braak&#x02264;3), pathologic aging (Braak&#x02264;3) and elderly control brains (Braak&#x02264;3) without neurodegenerative diagnoses. Age at death&#x02264;60.</td><td rowspan="2" align="left" valign="top" charoff="50">Gene expression phenotypes, covariates</td><td rowspan="2" align="left" valign="top" charoff="50">IlluminaHiSeq2000, 101 bp, paired end RNAseq</td><td rowspan="2" align="left" valign="top" charoff="50">NA</td></tr><tr><td align="left" valign="top" charoff="50">Mayo Brain Bank and Banner Sun Health/Cerebellum</td><td align="left" valign="top" charoff="50"><italic>N</italic>=86 AD, 84 PSP, 28 pathologic aging, 80 controls</td></tr></tbody></table></table-wrap><table-wrap position="float" id="t2"><label>Table 2</label><caption><title>Demographics for the cohorts included in each of the four studies.</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="char" char="("/><col align="char" char="("/><col align="char" char="("/><col align="char" char="("/><col align="char" char="("/><col align="char" char="("/><col align="char" char="("/><col align="char" char="("/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50">&#x000a0;</th><td>&#x000a0;</td><td>&#x000a0;</td><th colspan="2" align="center" valign="top" char="(" charoff="50"><bold>A. Mayo LOAD GWAS (Data Citation 2)</bold><hr/></th><th colspan="2" align="center" valign="top" char="(" charoff="50"><bold>B. Mayo eGWAS (Data Citations 3,4)</bold><hr/></th><th colspan="2" align="center" valign="top" char="(" charoff="50"><bold>C. Mayo Pilot RNAseq (Data Citation 5)</bold><hr/></th></tr><tr><th align="left" valign="top" charoff="50">&#x000a0;</th><th align="center" valign="top" char="(" charoff="50">&#x000a0;</th><th align="center" valign="top" char="(" charoff="50">&#x000a0;</th><th colspan="2" align="center" valign="top" char="(" charoff="50"><bold>TCX</bold><hr/></th><th colspan="2" align="center" valign="top" char="(" charoff="50"><bold>CER</bold><hr/></th><th colspan="2" align="center" valign="top" char="(" charoff="50"><bold>TCX</bold><hr/></th></tr><tr><th align="left" valign="top" charoff="50"><bold>Variables</bold></th><th align="center" valign="top" char="(" charoff="50"><bold>AD (</bold><italic>n</italic>=<bold>844)</bold></th><th align="center" valign="top" char="(" charoff="50"><bold>CON (1,255)</bold></th><th align="center" valign="top" char="(" charoff="50"><bold>AD (</bold><italic>n</italic>=<bold>202)</bold></th><th align="center" valign="top" char="(" charoff="50"><bold>NON-AD (</bold><italic>n</italic>=<bold>197)</bold></th><th align="center" valign="top" char="(" charoff="50"><bold>AD (</bold><italic>n</italic>=<bold>197)</bold></th><th align="center" valign="top" char="(" charoff="50"><bold>NON-AD (</bold><italic>n</italic>=<bold>177)</bold></th><th align="center" valign="top" char="(" charoff="50"><bold>AD (</bold><italic>n</italic>=<bold>94)</bold></th><th align="center" valign="top" char="(" charoff="50"><bold>PSP (</bold><italic>N</italic>=<bold>92)</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50"><bold>Mean Age</bold>&#x000b1;<bold>s.d. (Range)</bold></td><td align="char" valign="top" char="(" charoff="50">74.0&#x000b1;4.8 (60&#x02013;80)</td><td align="char" valign="top" char="(" charoff="50">73.2&#x000b1;4.4 (60&#x02013;80)</td><td align="char" valign="top" char="(" charoff="50">73.6&#x000b1;5.5 (60&#x02013;80)</td><td align="char" valign="top" char="(" charoff="50">71.6&#x000b1;5.6 (60&#x02013;80)</td><td align="char" valign="top" char="(" charoff="50">73.6&#x000b1;5.6 (60&#x02013;80)</td><td align="char" valign="top" char="(" charoff="50">71.7&#x000b1;5.5 (60&#x02013;80)</td><td align="char" valign="top" char="(" charoff="50">74.1&#x000b1;5.7 (60&#x02013;80)</td><td align="char" valign="top" char="(" charoff="50">71.9&#x000b1;5.4 (60&#x02013;80)</td></tr><tr><td align="left" valign="top" charoff="50"><bold>APOE4 positive/negative/null (%APOE4 positive)</bold></td><td align="char" valign="top" char="(" charoff="50">549/277/18 (65%)</td><td align="char" valign="top" char="(" charoff="50">344/889/22 (27%)</td><td align="char" valign="top" char="(" charoff="50">123/79/0 (61%)</td><td align="char" valign="top" char="(" charoff="50">49/146/2 (25%)</td><td align="char" valign="top" char="(" charoff="50">126/71/0 (64%)</td><td align="char" valign="top" char="(" charoff="50">45/130/2 (25%)</td><td align="char" valign="top" char="(" charoff="50">58/36/0 (62%)</td><td align="char" valign="top" char="(" charoff="50">20/72/0 (22%)</td></tr><tr><td align="left" valign="top" charoff="50"><bold>Female (%)</bold></td><td align="char" valign="top" char="(" charoff="50">482 (57%)</td><td align="char" valign="top" char="(" charoff="50">641 (51%)</td><td align="char" valign="top" char="(" charoff="50">108 (53%)</td><td align="char" valign="top" char="(" charoff="50">78 (40%)</td><td align="char" valign="top" char="(" charoff="50">101 (51%)</td><td align="char" valign="top" char="(" charoff="50">63 (36%)</td><td align="char" valign="top" char="(" charoff="50">41 (44%)</td><td align="char" valign="top" char="(" charoff="50">37 (40%)</td></tr><tr><td align="left" valign="top" charoff="50"><bold>Mean RIN</bold>&#x000b1;<bold>s.d. (Range)</bold></td><td align="center" valign="top" char="(" charoff="50">NA</td><td align="center" valign="top" char="(" charoff="50">NA</td><td align="char" valign="top" char="(" charoff="50">6.3&#x000b1;0.9 (5&#x02013;9)</td><td align="char" valign="top" char="(" charoff="50">6.9&#x000b1;1.0 (5&#x02013;9.3)</td><td align="char" valign="top" char="(" charoff="50">7.2&#x000b1;1.0 (5&#x02013;9.4)</td><td align="char" valign="top" char="(" charoff="50">7.2&#x000b1;1.0 (5&#x02013;9)</td><td align="char" valign="top" char="(" charoff="50">7.0&#x000b1;0.7 (6.2&#x02013;9)</td><td align="char" valign="top" char="(" charoff="50">7.0&#x000b1;0.9 (5.7&#x02013;9.3)</td></tr></tbody></table><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="char" char="("/><col align="char" char="("/><col align="char" char="("/><col align="char" char="("/><col align="char" char="("/><col align="char" char="("/><col align="char" char="("/><col align="char" char="("/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50">&#x000a0;</th><th colspan="4" align="center" valign="top" char="(" charoff="50"><bold>D. Mayo RNAseq (Data Citations 6,7)</bold><hr/></th><td>&#x000a0;</td><td>&#x000a0;</td><td>&#x000a0;</td><td>&#x000a0;</td></tr><tr><th align="left" valign="top" charoff="50">&#x000a0;</th><th colspan="4" align="center" valign="top" char="(" charoff="50"><bold>TCX</bold><hr/></th><th colspan="4" align="center" valign="top" char="(" charoff="50"><bold>CER</bold><hr/></th></tr><tr><th align="left" valign="top" charoff="50"><bold>Variables</bold></th><th align="center" valign="top" char="(" charoff="50"><bold>AD (</bold><italic>n</italic>=<bold>84)</bold></th><th align="center" valign="top" char="(" charoff="50"><bold>PSP (</bold><italic>n</italic>=<bold>84)</bold></th><th align="center" valign="top" char="(" charoff="50"><bold>Path Aging (</bold><italic>n</italic>=<bold>30)</bold></th><th align="center" valign="top" char="(" charoff="50"><bold>Control (</bold><italic>n</italic>=<bold>80)</bold></th><th align="center" valign="top" char="(" charoff="50"><bold>AD (</bold><italic>n</italic>=<bold>86)</bold></th><th align="center" valign="top" char="(" charoff="50"><bold>PSP (</bold><italic>n</italic>=<bold>84)</bold></th><th align="center" valign="top" char="(" charoff="50"><bold>Path Aging (</bold><italic>n</italic>=<bold>28)</bold></th><th align="center" valign="top" char="(" charoff="50"><bold>Control (</bold><italic>n</italic>=<bold>80)</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50"><bold>Mean Age</bold>&#x000b1;<bold>s.d. (Range)</bold></td><td align="char" valign="top" char="(" charoff="50">82.4&#x000b1;7.7 (60&#x02013;90)</td><td align="char" valign="top" char="(" charoff="50">74.0&#x000b1;6.5 (61&#x02013;89)</td><td align="char" valign="top" char="(" charoff="50">85.2&#x000b1;4.3 (76&#x02013;90)</td><td align="char" valign="top" char="(" charoff="50">82.6&#x000b1;8.8 (53&#x02013;90)</td><td align="char" valign="top" char="(" charoff="50">82.5&#x000b1;7.7 (60&#x02013;90)</td><td align="char" valign="top" char="(" charoff="50">74.0&#x000b1;6.5 (61&#x02013;89)</td><td align="char" valign="top" char="(" charoff="50">84.7&#x000b1;4.3 (76&#x02013;90)</td><td align="char" valign="top" char="(" charoff="50">82.5&#x000b1;8.3 (58&#x02013;90)</td></tr><tr><td align="left" valign="top" charoff="50"><bold>APOE4 positive/negative (%APOE4 positive)</bold></td><td align="char" valign="top" char="(" charoff="50">43/41 (51%)</td><td align="char" valign="top" char="(" charoff="50">13/71 (15%)</td><td align="char" valign="top" char="(" charoff="50">10/20 (33%)</td><td align="char" valign="top" char="(" charoff="50">10/70 (13%)</td><td align="char" valign="top" char="(" charoff="50">43/43 (50%)</td><td align="char" valign="top" char="(" charoff="50">13/71 (15%)</td><td align="char" valign="top" char="(" charoff="50">9/19 (32%)</td><td align="char" valign="top" char="(" charoff="50">11/69 (14%)</td></tr><tr><td align="left" valign="top" charoff="50"><bold>Female (%)</bold></td><td align="char" valign="top" char="(" charoff="50">48 (57%)</td><td align="char" valign="top" char="(" charoff="50">33 (39%)</td><td align="char" valign="top" char="(" charoff="50">17 (57%)</td><td align="char" valign="top" char="(" charoff="50">39 (49%)</td><td align="char" valign="top" char="(" charoff="50">49 (57%)</td><td align="char" valign="top" char="(" charoff="50">33 (39%)</td><td align="char" valign="top" char="(" charoff="50">16 (57%)</td><td align="char" valign="top" char="(" charoff="50">39 (49%)</td></tr><tr><td align="left" valign="top" charoff="50"><bold>Mean RIN</bold>&#x000b1;<bold>s.d. (Range)</bold></td><td align="char" valign="top" char="(" charoff="50">8.6&#x000b1;0.5 (7.7&#x02013;10.0)</td><td align="char" valign="top" char="(" charoff="50">8.5&#x000b1;0.5 (7.8&#x02013;10.0)</td><td align="char" valign="top" char="(" charoff="50">7.4&#x000b1;1.0 (5.3&#x02013;8.9)</td><td align="char" valign="top" char="(" charoff="50">7.6&#x000b1;1.0 (5.3&#x02013;9.7)</td><td align="char" valign="top" char="(" charoff="50">8.3&#x000b1;0.8 (5.7&#x02013;10.0)</td><td align="char" valign="top" char="(" charoff="50">8.4&#x000b1;0.9 (5.5&#x02013;10.0)</td><td align="char" valign="top" char="(" charoff="50">7.5&#x000b1;1.0 (5.7&#x02013;9.0)</td><td align="char" valign="top" char="(" charoff="50">7.6&#x000b1;1.0 (5.5&#x02013;9.7)</td></tr></tbody></table></table-wrap><table-wrap position="float" id="t3"><label>Table 3</label><caption><title>Description of data files deposited in the AMP-AD Knowledge Portal.</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"><bold>Study Name</bold></th><th align="left" valign="top" charoff="50"><bold>doi</bold></th><th align="left" valign="top" charoff="50"><bold>Data Type</bold></th><th align="left" valign="top" charoff="50"><bold>File Name</bold></th><th align="left" valign="top" charoff="50"><bold>doi</bold></th><th align="left" valign="top" charoff="50"><bold>File Type</bold></th><th align="left" valign="top" charoff="50"><bold>File Column Headers Definitions</bold></th><th align="left" valign="top" charoff="50"><bold>Reference</bold></th></tr></thead><tfoot valign="top"><tr><th align="left" valign="top" charoff="50">The Genotype and Covariate data from the Mayo LOAD GWAS study (A) and the eSNP results under the Mayo eGWAS study (B) were previously made available through the NIAGADS respository: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.niagads.org/datasets/ng00043">https://www.niagads.org/datasets/ng00043</ext-link> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.niagads.org/datasets/ng00025">https://www.niagads.org/datasets/ng00025</ext-link> respectively.</th><td>&#x000a0;</td><td>&#x000a0;</td><td>&#x000a0;</td><td>&#x000a0;</td><td>&#x000a0;</td><td>&#x000a0;</td><td>&#x000a0;</td></tr></tfoot><tbody valign="top"><tr><td rowspan="4" align="left" valign="top" charoff="50">A. Mayo LOAD GWAS (Data Citation 2)</td><td rowspan="4" align="left" valign="top" charoff="50">10.7303/syn2910256</td><td rowspan="4" align="left" valign="top" charoff="50">Genotype and Covariate</td><td align="left" valign="top" charoff="50">MayoLOADGWAS_SNPGenotypes_covariates.csv</td><td align="left" valign="top" charoff="50">10.7303/syn3205821.6</td><td align="left" valign="top" charoff="50">Covariate information for subjects included in Mayo LOAD GWAS, comma delimited text file</td><td align="left" valign="top" charoff="50">FID=Family ID; IID=Individual ID; RSGWAS=&#x02018;1&#x02019; indicates if sample is part of Mayo Clinic Rochester Antemortem Cohort; AUTGWAS=&#x02018;1&#x02019; indicates if sample is part of Mayo Clinic Brain Bank Postmortem Cohort; AgeOver60=number of years beyond the age of 60 for age at death (Mayo Clinic Brain Bank Postmortem Cohort) or age at diagnosis (Mayo Clinic Rochester and Jacksonville Antemortem Cohorts); Sex=1 if Male; APOE4_Dose (+/&#x02212;)=&#x02018;1&#x02019; indicates carriers of at least one copy of the APOE&#x003b5;4 allele; APOE4_dosage (0,1,2)= number of APOE&#x003b5;4 alleles ; APOE_Genotype=APOE genotype calls. For all columns &#x02018;&#x02212;9&#x02019; indicates missing data.</td><td rowspan="4" align="left" valign="top" charoff="50">Carrasquillo <italic>et al.</italic>, <sup><xref ref-type="bibr" rid="b1">1</xref></sup>, Nature Genetics</td></tr><tr><td align="left" valign="top" charoff="50">MayoLOADGWAS_SNPGenotypes.bed</td><td align="left" valign="top" charoff="50">10.7303/syn3205812.4</td><td align="left" valign="top" charoff="50">LOAD GWAS binary ped file (PLINK format), genotype information</td><td align="left" valign="top" charoff="50">Binary File, No Column Headers.</td></tr><tr><td align="left" valign="top" charoff="50">MayoLOADGWAS_SNPGenotypes.bim</td><td align="left" valign="top" charoff="50">10.7303/syn3205814.4</td><td align="left" valign="top" charoff="50">LOAD GWAS binary map file (PLINK format), variant information</td><td align="left" valign="top" charoff="50">Binary File, No Column Headers.</td></tr><tr><td align="left" valign="top" charoff="50">MayoLOADGWAS_SNPGenotypes.fam</td><td align="left" valign="top" charoff="50">10.7303/syn3205816.4</td><td align="left" valign="top" charoff="50">LOAD GWAS fam file (PLINK format), pedigree and phenotype information</td><td align="left" valign="top" charoff="50">Six columns: Column 1=Family ID; Column 2= Individual ID; Column 3=Paternal ID; Column 4=Maternal ID; Column 5=Sex (1=male; 2=female); Column 6=Phenotype (1=control; 2= AD case)</td></tr><tr><td rowspan="16" align="left" valign="top" charoff="50">B. Mayo eGWAS (Data Citation 3,Data Citation 4)</td><td rowspan="4" align="left" valign="top" charoff="50">10.7303/syn3157225</td><td rowspan="4" align="left" valign="top" charoff="50">Array Expression and Covariate (Data Citation 3)</td><td align="left" valign="top" charoff="50">MayoEGWAS_arrayExpression_CBE_covariates.csv</td><td align="left" valign="top" charoff="50">10.7303/syn3256502.1</td><td align="left" valign="top" charoff="50">Covariate information for subjects with cerebellum expression measures, comma delimited text file.</td><td rowspan="2" align="left" valign="top" charoff="50">Dxn=Diagnosis (0=Non-AD, 1=AD); Sex=1 if female and 0 if male; Age=Age at Death; E4dose=Number of APOE&#x003b5;4 alleles; plate1-plate4 (cerebellum) or plate 2-plate 5 (temporal cortex)=PCR plate - technical covariate; RIN=RNA intergrity number - a numerical assessment of the integrity of RNA; RINsqAdj=(RIN-RINmean)^2 - a statistical adjustment of the RIN.</td><td rowspan="16" align="left" valign="top" charoff="50">Zou <italic>et al.</italic>, <sup><xref ref-type="bibr" rid="b10">10</xref></sup>, PLoS Genetics</td></tr><tr><td align="left" valign="top" charoff="50">MayoEGWAS_arrayExpression_TCX_covariates.csv</td><td align="left" valign="top" charoff="50">10.7303/syn3617056.1</td><td align="left" valign="top" charoff="50">Covariate information for subjects with temporal cortex expression measures, comma delimited text file.</td></tr><tr><td align="left" valign="top" charoff="50">MayoEGWAS_arrayExpression_CBE.csv</td><td align="left" valign="top" charoff="50">10.7303/syn3256501.1</td><td align="left" valign="top" charoff="50">Gene expression phenotypes from cerebellum tissue samples, comma delimited text file.</td><td rowspan="2" align="left" valign="top" charoff="50">FID=Family ID; IID=Individual ID; ILMN_1762337 to ILMN_2137536=WG-DASL Illumina Probe ID.</td></tr><tr><td align="left" valign="top" charoff="50">MayoEGWAS_arrayExpression_TCX.csv</td><td align="left" valign="top" charoff="50">10.7303/syn3617054.1</td><td align="left" valign="top" charoff="50">Gene expression phenotypes from temporal cortex tissue samples, comma delimited text file.</td></tr><tr><td rowspan="12" align="left" valign="top" charoff="50">10.7303/syn3157249</td><td rowspan="12" align="left" valign="top" charoff="50">eSNP Results (Data Citation 4)</td><td align="left" valign="top" charoff="50">MayoEGWAS_analysis_eQTL_CBE_results_AD.gz</td><td align="left" valign="top" charoff="50">10.7303/syn3207163.3</td><td align="left" valign="top" charoff="50">Brain expression GWAS (eGWAS) results obtained using Hap300 genotypes in the cerebellar samples of the AD subjects, text file with 444,372 rows.</td><td rowspan="6" align="left" valign="top" charoff="50">CHR=Chromosome; SNP=SNP rs number; BP=Physical position (base-pair) according to NCBI Ref Seq, Build 36.2; A1=Tested Allele; TEST=The &#x02018;additive&#x02019; SNP genotype test; NMISS=Number of non-missing individuals included in analysis; BETA=Regression coefficient. Based on the SNP minor allele using an additive model; STAT=Coefficient t-statistic; P=Asymptotic p-value for t-statistic (uncorrected); PROBE=WG-DASL Illumina Probe ID; txStart=Starting base pair for the RefSeq gene the brain level of which is tested for associations. (Based on Build 36.2); txEnd=Ending base pair for the RefSeq gene the brain level of which is tested for associations. (Based on Build 36.2); SYMBOL=Gene symbol for the RefSeq gene tested in the eGWAS; hasSNP=If the probe sequence harbors &#x02265;1 SNPs, then this is shown as &#x02018;TRUE&#x02019; under the &#x02018;SNP-In-Probe&#x02019; column, and &#x02018;FALSE&#x02019;, otherwise.</td></tr><tr><td align="left" valign="top" charoff="50">MayoEGWAS_analysis_eQTL_CBE_results_nonAD.gz</td><td align="left" valign="top" charoff="50">10.7303/syn3207167.3</td><td align="left" valign="top" charoff="50">Brain expression GWAS (eGWAS) results obtained using Hap300 genotypes in the cerebellar samples of the non-AD subjects, text file with 443,171 rows</td></tr><tr><td align="left" valign="top" charoff="50">MayoEGWAS_analysis_eQTL_CBE_results.gz</td><td align="left" valign="top" charoff="50">10.7303/syn3207165.3</td><td align="left" valign="top" charoff="50">Brain expression GWAS (eGWAS) results obtained using Hap300 genotypes in the cerebellar samples of the combined AD and non-AD subjects, text file with 443,784 rows</td></tr><tr><td align="left" valign="top" charoff="50">MayoEGWAS_analysis_eQTL_TCX_results_AD.gz</td><td align="left" valign="top" charoff="50">10.7303/syn3207169.3</td><td align="left" valign="top" charoff="50">Brain expression GWAS (eGWAS) results obtained using Hap300 genotypes in the temporal cortex samples of the AD subjects, text file with 450,813 rows.</td></tr><tr><td align="left" valign="top" charoff="50">MayoEGWAS_analysis_eQTL_TCX_results_nonAD.gz</td><td align="left" valign="top" charoff="50">10.7303/syn3207175.3</td><td align="left" valign="top" charoff="50">Brain expression GWAS (eGWAS) results obtained using Hap300 genotypes in the temporal cortex samples of the non-AD subjects, text file with 440,065 rows.</td></tr><tr><td align="left" valign="top" charoff="50">MayoEGWAS_analysis_eQTL_TCX_results.gz</td><td align="left" valign="top" charoff="50">10.7303/syn3207173.3</td><td align="left" valign="top" charoff="50">Brain expression GWAS (eGWAS) results obtained using Hap300 genotypes in the temporal cortex samples of the combined AD and non-AD subjects, text file with 445,356 rows.</td></tr><tr><td align="left" valign="top" charoff="50">MayoEGWAS_analysis_eQTL_CBE_imputedResults_AD.gz</td><td align="left" valign="top" charoff="50">10.7303/syn3207177.3</td><td align="left" valign="top" charoff="50">Brain expression GWAS (eGWAS) results obtained using HapMap2 imputed genotypes in the cerebellar samples of the AD subjects, text file with 4,427,924 rows.</td><td rowspan="6" align="left" valign="top" charoff="50">CHR=Chromosome; SNP=SNP rs number; BP=Physical position (base-pair) according to NCBI Ref Seq, Build 36.2; A1=Tested Allele; TEST=The &#x02018;additive&#x02019; SNP genotype test; NMISS=Number of non-missing individuals included in analysis; BETA=Regression coefficient. Based on the SNP minor allele using an additive model; STAT=Coefficient t-statistic; P=Asymptotic p-value for t-statistic (uncorrected); PROBE=WG-DASL Illumina Probe ID; txStart=Starting base pair for the RefSeq gene the brain level of which is tested for associations. (Based on Build 36.2); txEnd=Ending base pair for the RefSeq gene the brain level of which is tested for associations. (Based on Build 36.2); SYMBOL=Gene symbol for the RefSeq gene tested in the eGWAS; hasSNP=If the probe sequence harbors &#x02265;1 SNPs, then this is shown as &#x02018;TRUE&#x02019; under the &#x02018;SNP-In-Probe&#x02019; column, and &#x02018;FALSE&#x02019;, otherwise. We also calculated for each probe within each analytic group, percent detection rate above background. Probes that are detected in &#x0003e;12.5%, &#x0003e;25%, &#x0003e;50% and &#x0003e;75% of the subjects in each analytic group are annotated by four separate columns labeled respectively and indicated with &#x02018;TRUE&#x02019; and &#x02018;FALSE&#x02019; statetments.</td></tr><tr><td align="left" valign="top" charoff="50">MayoEGWAS_analysis_eQTL_CBE_imputedResults_nonAD.gz</td><td align="left" valign="top" charoff="50">10.7303/syn3207181.3</td><td align="left" valign="top" charoff="50">Brain expression GWAS (eGWAS) results obtained using HapMap2 imputed genotypes in the cerebellar samples of the non-AD subjects, text file with 4,419,055 rows</td></tr><tr><td align="left" valign="top" charoff="50">MayoEGWAS_analysis_eQTL_CBE_imputedResults.gz</td><td align="left" valign="top" charoff="50">10.7303/syn3207179.3</td><td align="left" valign="top" charoff="50">Brain expression GWAS (eGWAS) results obtained using HapMap2 imputed genotypes in the cerebellar samples of the combined AD and non-AD subjects, text file with 4,483,512 rows</td></tr><tr><td align="left" valign="top" charoff="50">MayoEGWAS_analysis_eQTL_TCX_imputedResults_AD.gz</td><td align="left" valign="top" charoff="50">10.7303/syn3207183.3</td><td align="left" valign="top" charoff="50">Brain expression GWAS (eGWAS) results obtained using HapMap2 imputed genotypes in the temporal cortex samples of the AD subjects, text file with 4,426,363 rows.</td></tr><tr><td align="left" valign="top" charoff="50">MayoEGWAS_analysis_eQTL_TCX_imputedResults_nonAD.gz</td><td align="left" valign="top" charoff="50">10.7303/syn3207187.3</td><td align="left" valign="top" charoff="50">Brain expression GWAS (eGWAS) results obtained using HapMap2 imputed genotypes in the temporal cortex samples of the non-AD subjects, text file with 4,425,955 rows.</td></tr><tr><td align="left" valign="top" charoff="50">MayoEGWAS_analysis_eQTL_TCX_imputedResults.gz</td><td align="left" valign="top" charoff="50">10.7303/syn3207185.3</td><td align="left" valign="top" charoff="50">Brain expression GWAS (eGWAS) results obtained using HapMap2 imputed genotypes in the temporal cortex samples of the combined AD and non-AD subjects, text file with 4,484,344 rows.</td></tr><tr><td rowspan="12" align="left" valign="top" charoff="50">C. Mayo Pilot RNAseq (Data Citation 5)</td><td rowspan="12" align="left" valign="top" charoff="50">10.7303/syn3157268</td><td rowspan="12" align="left" valign="top" charoff="50">RNA-seq Alignment, Expression and Covariate</td><td align="left" valign="top" charoff="50">MayoPilotRNAseq Alzheimers Disease RNAseq BAMs</td><td align="left" valign="top" charoff="50">10.7303/syn5580964</td><td align="left" valign="top" charoff="50">Folder of BAM alignment files, 1 file per sample. Sample ID (IID) for each subject is provided in the first 12 digits of each file name.</td><td rowspan="2" align="left" valign="top" charoff="50">NA</td><td rowspan="12" align="left" valign="top" charoff="50">Allen <italic>et al.</italic>, <sup><xref ref-type="bibr" rid="b18">18</xref></sup>, Neurology:Genetics</td></tr><tr><td align="left" valign="top" charoff="50">MayoPilotRNAseq Progressive Supranuclear Palsy RNAseq BAMs</td><td align="left" valign="top" charoff="50">10.7303/syn5584594</td><td align="left" valign="top" charoff="50">Folder of BAM alignment files, 1 file per sample. Sample ID (IID) for each subject is provided in the first 12 digits of each file name.</td></tr><tr><td align="left" valign="top" charoff="50">MayoPilotRNAseq_RNAseq_TCX_AD_covariates.csv</td><td align="left" valign="top" charoff="50">10.7303/syn3607480.2</td><td align="left" valign="top" charoff="50">Covariate information for AD subjects with temporal cortex expression measures, comma delimited text file.</td><td rowspan="2" align="left" valign="top" charoff="50">IlluminaSampleID=Individual ID (matches corresponding IID in Mayo LOAD GWAS files); Sex=M if Male and F if Female; Age at death; RIN=RNA intergrity number - a numerical assessment of the integrity of RNA; RINsqAdj=(RIN-RINmean)^2 - a statistical adjustment of the RIN; Library Batch=RNAseq library preparation batch; FCC1MR9ACXX - FCD1LUUACXX (AD) or FCD1GH3ACXX -FCC1CDJACXX (PSP)=&#x02018;1&#x02019; indicates sample was on sequencing flowcell - technical covariate; Flowcell=sequencing flowcell name.</td></tr><tr><td align="left" valign="top" charoff="50">MayoPilotRNAseq_RNAseq_TCX_PSP_covariates.csv</td><td align="left" valign="top" charoff="50">10.7303/syn3607506.1</td><td align="left" valign="top" charoff="50">Covariate information for PSP subjects with temporal cortex expression measures, comma delimited text file.</td></tr><tr><td align="left" valign="top" charoff="50">MayoPilotRNAseq_RNAseq_TCX_AD_geneCounts.tsv</td><td align="left" valign="top" charoff="50">10.7303/syn3607482.2</td><td align="left" valign="top" charoff="50">Gene expression phenotypes from AD temporal cortex tissue samples, space delimited text file with 64,254 rows.</td><td rowspan="2" align="left" valign="top" charoff="50">Column 1=Ensemble Gene IDs; 1823480105_B - 1796012340_B=Illumina Sample ID's (matches corresponding IID in Mayo LOAD GWAS files).</td></tr><tr><td align="left" valign="top" charoff="50">MayoPilotRNAseq_RNAseq_TCX_AD_geneCounts_normalized.tsv</td><td align="left" valign="top" charoff="50">10.7303/syn3607497.1</td><td align="left" valign="top" charoff="50">Normalized gene expression phenotypes from AD temporal cortex tissue samples, tab delimited text file with 64,254 rows</td></tr><tr><td align="left" valign="top" charoff="50">MayoPilotRNAseq_RNAseq_TCX_AD_transcriptCounts.tsv</td><td align="left" valign="top" charoff="50">10.7303/syn3607485.2</td><td align="left" valign="top" charoff="50">Transcript expression phenotypes from AD temporal cortex tissue samples, space delimited text file with 208,245 rows.</td><td rowspan="2" align="left" valign="top" charoff="50">Column 1=Ensemble Transcript IDs; 1823480105_B - 1796012340_B=Illumina Sample ID's (matches corresponding IID in Mayo LOAD GWAS files).</td></tr><tr><td align="left" valign="top" charoff="50">MayoPilotRNAseq_RNAseq_TCX_AD_transcriptCounts_normalized.tsv</td><td align="left" valign="top" charoff="50">10.7303/syn3607502.1</td><td align="left" valign="top" charoff="50">Normalized transcript expression phenotypes from AD temporal cortex tissue samples, tab delimited text file with 208,245 rows.</td></tr><tr><td align="left" valign="top" charoff="50">MayoPilotRNAseq_RNAseq_TCX_PSP_geneCounts.tsv</td><td align="left" valign="top" charoff="50">10.7303/syn3607487.2</td><td align="left" valign="top" charoff="50">Gene expression phenotypes from PSP temporal cortex tissue samples, space delimited text file with 64,254 rows</td><td rowspan="2" align="left" valign="top" charoff="50">Column 1=Ensemble Gene IDs; 1811024586_A - 1811024534_A=Illumina Sample ID's (matches corresponding IID in Mayo LOAD GWAS files).</td></tr><tr><td align="left" valign="top" charoff="50">MayoPilotRNAseq_RNAseq_TCX_PSP_geneCounts_normalized.tsv</td><td align="left" valign="top" charoff="50">10.7303/syn3607513.1</td><td align="left" valign="top" charoff="50">Normalized gene expression phenotypes from PSP temporal cortex tissue samples, tab delimited text file with 64,254 rows</td></tr><tr><td align="left" valign="top" charoff="50">MayoPilotRNAseq_RNAseq_TCX_PSP_transcriptCounts.tsv</td><td align="left" valign="top" charoff="50">10.7303/syn3607489.2</td><td align="left" valign="top" charoff="50">Transcript expression phenotypes from PSP temporal cortex tissue samples, space delimited text file with 208,245 rows.</td><td rowspan="2" align="left" valign="top" charoff="50">Column 1=Ensemble Transcript IDs; 1811024586_A - 1811024534_A=Illumina Sample ID's (matches corresponding IID in Mayo LOAD GWAS files).</td></tr><tr><td align="left" valign="top" charoff="50">MayoPilotRNAseq_RNAseq_TCX_PSP_transcriptCounts_normalized.tsv</td><td align="left" valign="top" charoff="50">10.7303/syn3607519.1</td><td align="left" valign="top" charoff="50">Normalized transcript expression phenotypes from PSP temporal cortex tissue samples, tab delimited text file with 208,245 rows.</td></tr><tr><td rowspan="13" align="left" valign="top" charoff="50">D. Mayo RNAseq (Data Citation 6,Data Citation 7)</td><td rowspan="6" align="left" valign="top" charoff="50">10.7303/syn3163039</td><td rowspan="6" align="left" valign="top" charoff="50">TCX RNA-seq Alignment, Expression and Covariate (Data Citation 6)</td><td align="left" valign="top" charoff="50">MayoRNAseq Temporal Cortex BAMs</td><td align="left" valign="top" charoff="50">10.7303/syn4894912</td><td align="left" valign="top" charoff="50">Folder of BAM alignment files, 1 file per sample. Sample ID (IID) for each subject is provided in the first 6 to 8 digits of each file name.</td><td align="left" valign="top" charoff="50">NA</td><td rowspan="13" align="left" valign="top" charoff="50">NA</td></tr><tr><td align="left" valign="top" charoff="50">MayoRNAseq_RNAseq_TCX_covariates.csv</td><td align="left" valign="top" charoff="50">10.7303/syn3817650.5</td><td align="left" valign="top" charoff="50">Covariate information for subjects with temporal cortex expression measures, comma delimited text file.</td><td align="left" valign="top" charoff="50">Sample ID=3 to 5 digit unique sample identifier followed by _TCX; Source=Pathology lab that provided the tissue; Tissue=Brain region sampled; RIN=RNA intergrity number - a numerical assessment of the integrity of RNA; Diagnosis=Pathological diagnosis at time of death (AD=Alzheimer's Disease; PSP=Progressive Supranuclear Palsy; Pathologic Aging; Control); Sex=M if Male, F if Female; AgeAtDeath; Flowcell=sequencing flowcell.</td></tr><tr><td align="left" valign="top" charoff="50">MayoRNAseq_RNAseq_TCX_geneCounts.tsv</td><td align="left" valign="top" charoff="50">10.7303/syn4650257.8</td><td align="left" valign="top" charoff="50">Gene expression phenotypes, temporal cortex tissue samples, space delimited text file with 64,254 rows</td><td rowspan="2" align="left" valign="top" charoff="50">Column 1=Ensemble Gene IDs; 11344_TCX to 1047_TCX etc.=Sample ID's (matches corresponding SampleID in Covariate file).</td></tr><tr><td align="left" valign="top" charoff="50">MayoRNAseq_RNAseq_TCX_geneCounts_normalized.tsv</td><td align="left" valign="top" charoff="50">10.7303/syn4650265.4</td><td align="left" valign="top" charoff="50">Normalized gene expression phenotypes, temporal cortex tissue samples, tab delimited text file with 64,254 rows</td></tr><tr><td align="left" valign="top" charoff="50">MayoRNAseq_RNAseq_TCX_transcriptCounts.tsv</td><td align="left" valign="top" charoff="50">10.7303/syn5600752.2</td><td align="left" valign="top" charoff="50">Transcript expression phenotypes, temporal cortex tissue samples, space delimited text file with 208,245 rows</td><td rowspan="2" align="left" valign="top" charoff="50">Column 1=Ensemble Transcript IDs; 11344_TCX to 1047_TCX etc.=Sample ID's (matches corresponding SampleID in Covariate file).</td></tr><tr><td align="left" valign="top" charoff="50">MayoRNAseq_RNAseq_TCX_transcriptCounts_normalized.tsv</td><td align="left" valign="top" charoff="50">10.7303/syn5600755.2</td><td align="left" valign="top" charoff="50">Normalized Transcript expression phenotypes, temporal cortex tissue samples, tab delimited text file with 208,245 rows</td></tr><tr><td rowspan="6" align="left" valign="top" charoff="50">10.7303/syn5049298</td><td align="left" valign="top" charoff="50">CER RNA-seq Alignment, Expression and Covariate (Data Citation 7)</td><td align="left" valign="top" charoff="50">MayoRNAseq Cerebellum BAMs</td><td align="left" valign="top" charoff="50">10.7303/syn5049322</td><td align="left" valign="top" charoff="50">Folder of BAM alignment files, 1 file per sample. Sample ID for each subject is provided in the first 6 to 8 digits of each file name.</td><td align="left" valign="top" charoff="50">NA</td></tr><tr><td align="left" valign="top" charoff="50">MayoRNAseq_RNAseq_CBE_covariates.csv</td><td align="left" valign="top" charoff="50">10.7303/syn5223705.2</td><td align="left" valign="top" charoff="50">Covariate information for subjects with cerebellum expression measures, comma delimited text file.</td><td align="left" valign="top" charoff="50">Sample ID=3 to 5 digit unique sample identifier followed by _CER; Source=Pathology lab that provided the tissue; Tissue=Brain region sampled; RIN=RNA intergrity number - a numerical assessment of the integrity of RNA; Diagnosis=Pathological diagnosis at time of death (AD=Alzheimer's Disease; PSP=Progressive Supranuclear Palsy; Pathologic Aging; Control); Sex=M if Male, F if Female; AgeAtDeath; ApoE=APOE genotype; Flowcell=sequencing flowcell.</td><td>&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">MayoRNAseq_RNAseq_CBE_geneCounts.tsv</td><td align="left" valign="top" charoff="50">10.7303/syn5201012.4</td><td align="left" valign="top" charoff="50">Gene expression phenotypes, cerebellum tissue samples, tab delimited text file with 64,254 rows</td><td rowspan="2" align="left" valign="top" charoff="50">Column 1=Ensemble Gene IDs; 1000_CER to 991_CER= Sample ID's (matches corresponding SampleID in Covariate file).</td><td>&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">MayoRNAseq_RNAseq_CBE_geneCounts_normalized.tsv</td><td align="left" valign="top" charoff="50">10.7303/syn5201007.4</td><td align="left" valign="top" charoff="50">Normalized gene expression phenotypes, cerebellum tissue samples, tab delimited text file with 64,254 rows</td><td>&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">MayoRNAseq_RNAseq_CBE_transcriptCounts.tsv</td><td align="left" valign="top" charoff="50">10.7303/syn5600773.2</td><td align="left" valign="top" charoff="50">Transcript expression phenotypes, cerebellum tissue samples, space delimited text file with 208,245 rows</td><td rowspan="2" align="left" valign="top" charoff="50">Column 1=Ensemble Transcript IDs; 1000_CER to 991_CER=Sample ID's (matches corresponding SampleID in Covariate file).</td><td>&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">MayoRNAseq_RNAseq_CBE_transcriptCounts_normalized.tsv</td><td align="left" valign="top" charoff="50">10.7303/syn5600772.2</td><td align="left" valign="top" charoff="50">Normalized Transcript expression phenotypes, cerebellum tissue samples, tab delimited text file with 208,245 rows</td><td>&#x000a0;</td></tr></tbody></table></table-wrap></floats-group></article>